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CANCER
All life on Earth is thought to share a common ancestor that lived roughly 3.5 billion years 
ago1-3. As simple life forms evolved, cooperation between unicellular organisms paved 
the way for more complex multicellular organisms. This process is elegantly visualized 
by culturing groups of the bacterium Pseudomonas Fluorescens. Individual bacteria 
spontaneously mutate to acquire a cell-cell glue, producing multicellular mats that are 
more effective in collecting oxygen4. These unicellular organisms promote their own 
evolutionary success by cooperating as a multicellular organism. In a similar manner, 
the approximate 4 x 1013 cells in our body also work together and prioritize the fitness 
of the organism above the prosperity of individual cells5. However, cooperation between 
cells is sometimes disrupted. In the example of Pseudomonas Fluorescens, ‘cheating’ 
bacteria arise that take advantage of the increased oxygen without contributing to 
the multicellular mats, eventually sending these groups of cells into their demise6. 
Cells in the human body can also develop characteristics that allow them to prosper at 
the expense of the entire organism. When these malignant cells behave according to 
several hallmarks, they are thought to be cancerous. Cancer cells induce proliferative 
signaling, evade growth suppressors, resist cell death, replicate uncontrollably, induce 
angiogenesis, and actively invade tissues7. Cancer can arise from virtually any tissue in 
the human body and is among the leading causes of morbidity worldwide8. Moreover, 
the number of new cancer cases is expected to rise by 70% in the coming decades8.
HEMATOPOIESIS AND THE BONE MARROW NICHE
All cells in the human body are connected to the blood system: a dynamic network of 
arteries and veins which transports two major types of blood cells. Red blood cells, or 
erythrocytes, transport O2 and CO2 bound to hemoglobin, while white blood cells (WBCs), 
or leukocytes, protect against infectious agents. Blood cells descent from a single cell 
type, the hematopoietic stem cell (HSC), which is maintained and regulated by the bone 
marrow (BM) microenvironment9-11. HSCs create progenitor cells devoted to producing 
specific lineages of mature blood cells12. Common myeloid progenitors produce myeloid 
cells (myeloid means resembling BM) and common lymphoid progenitors give rise to B 
cells and T cells. Combined, the blood system provides nutrients and oxygen, removes 
waste products and protects the entire body from pathogens. While all blood cells have 
a limited life span, HSCs are capable of self-renewal and producing additional HSCs. These 
characteristics are driven by chemical and physical interactions from the microenvironment 
in which HSCs reside9,13. The BM niche is rich in stem cell factor, stromal cell-derived factor 
1 (CXCL12), transforming growth factor beta-1, angiopoietin 1, thrombopoietin and 
platelet factor 4; while endothelial cells, megakaryocytes and mesenchymal stromal cells 
(MSCs) provide crucial cell-cell interactions that sustain HSCs9,14. Together these signals 
facilitate the hierarchy between HSCs and all other blood cells. HSCs are maintained to 
replenish the blood system, while mature blood cells undergo apoptosis upon completion 
of their task. 
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LEUKEMIA
Leukemia is a type of cancer that originates from the BM and disturbs the balance between 
blood cells. It is caused by WBCs that are transformed and proliferate uncontrollably. If 
left untreated, leukemia leads to severe symptoms and death. Leukemias are classified 
based on their phenotype. Acute leukemia is caused by a rapid increase of immature 
WBCs while chronic leukemia can take years to progress. Further subdivision is performed 
based on the origin of the malignant cell, which is either of the lymphoid or myeloid 
lineage. This thesis focuses on acute lymphoblastic leukemia (ALL), which is the most 
frequent cause of death from cancer among children15. More specifically, we focus on ALL 
that arises from B cell precursors (BCP-ALL), the most common form of ALL16. BCP-ALL 
cells are genetically altered compared to their healthy counterparts, often by changes 
in chromosome number and chromosome translocations15. Chromosome translocations 
produce recombined gene loci that alter the expression of oncogenes and induce chimeric 
fusion genes with transforming properties17,18. They are recognized as driving events 
in childhood leukemia and consequently, BCP-ALL are classified by their chromosomal 
rearrangement19. BCR-ABL1, ETV6-RUNX1, TCF3-PBX1, and MLL-rearranged leukemia 
account for more than one-third of the BCP-ALL cases20. Furthermore, 25% of cases 
show hyperdiploidy (> 50 chromosomes per leukemic cell)20. Finally, BCP-ALL with neither 
of the previous aberrations are classified as B-Other. Part of the B-Other leukemias have 
been observed by gene expression arrays to induce transcriptionally related programs to 
BCR-ABL1+ cells and are therefore called BCR-ABL1-like leukemia21. 
TREATMENT
Cytogenetically classifying leukemia predicts patient outcome and chemotherapy 
resistance20,22. This has been used to optimize treatment protocols, which has improved 
survival from 10% in the 1960’s to approximately 90% survival in the 21st century15. 
Other types of childhood cancer follow this trend although survival is on average 80%23. 
Improvements in treatment have brought about that 1 out of every 1000 twenty-year-olds 
is a survivor of childhood cancer24. Due to a lack of treatment specificity almost two third 
of survivors suffer from a chronic condition, and in 28% late effects are life-threatening25. 
Cardiac damage, severe pulmonary damage, fibrosis to the gastrointestinal tract, hepatitis 
and cirrhosis, kidney and bladder damage, skeletal damage, muscle atrophy, hyper and 
hypothyroidism, obesity, short stature, gonadal failure, damage to the central nervous 
system affecting cognitive abilities, cataracts, hearing loss, damaged teeth and gums; 
all are off-target effects of chemo and radiotherapy .24-40 Moreover, childhood cancer 
survivors are at more than 19-fold increased risk for developing another malignancy, 
caused in part by cancer therapy25,40. This underlines the importance of finding novel 
therapeutic options that specifically and effectively kill leukemic cells.
THE LEUKEMIC NICHE
To pinpoint new therapeutic targets, it is key to elucidate which cells drive leukemia and 
how these cells are transformed. Cancer cells resemble stem cells, as they share the ability 
to self-renew and are mostly driven by the same molecular pathways41. Simultaneous to 
the discovery of HSCs, it was observed that only low frequencies of leukemic cells could 
form colonies both in vitro and in vivo42-45. These findings pointed to the existence of 
leukemia stem cells (LSCs), also called leukemia propagating cells, which existence has 
been demonstrated for the first time in acute myeloid leukemia46. LSCs disrupt normal 
HSC niches47 and are unresponsive to the intrinsic and extrinsic cues that keep HSCs in 
check48. The disrupted, so called leukemic, niche is essential in initiating and facilitating 
leukemogenesis49-53. Current treatment is aimed at the bulk of leukemic cells, but arguably 
a more successful strategy would be to target the LSC. LSCs have increased resistance to 
chemotherapeutic agents and are protected from elimination by immune responses by 
the leukemic niche54-59. Therefore, disrupting the interaction between leukemic cells and 
their microenvironment offers a promising new therapeutic strategy. However, it is largely 
unclear how crosstalk occurs within the leukemic niche, and how this drives leukemic cell 
survival and chemotherapy resistance.
INTERCELLULAR COMMUNICATION
Communication between cells governs their behavior in favor of the organisms’ benefit. 
This importance of cell-cell communication is underlined by the broad amount of 
signaling mechanisms that have evolved in human cells (Figure 1). Signaling between 
nearby cells is facilitated by ligand-receptor interactions and through electrical signals 
exchanged via specialized structures called gap junctions. Cells that communicate over 
(long) distances use cytokines, vesicles, hormones or even dissolved gases like nitric oxide 
that spread via the blood system. However, current knowledge on intercellular signaling 
is lacking in its ability to explain interactions in the leukemic niche. In 2004, cytoskeletal 
structures called tunneling nanotubes (TNTs), or membrane nanotubes, were discovered 
to facilitate signaling between eukaryotic cells60-62. TNTs protrude from the cell membrane 
and are driven by the polymerization of monomeric actin into filamentous actin61,62 
(Figure 1 and 2). They can reach lengths of multiple cell diameters and facilitate intercellular 
signaling of diverse cargo, including organelles, pathogens, calcium fluxes, membrane 
bound proteins and death signals61,63-66. TNTs have been observed in numerous cell types, 
like cancer cells, complex tissues and organisms61,62,65,67-71. Their pathophysiological 
importance has been demonstrated by studies showing the spread of prions and HIV-1 
particles via TNTs62,72. However, their presence and importance in the leukemic niche have 
not yet been addressed. The broad array of signal molecules that may be exchanged 
between leukemic cells and the BM microenvironment via TNTs make these structures 
prime candidates for investigation.
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receptor CXCR476. Disturbance of the CXCR4/CXCL12 axis, by treatment with cytokines 
or CXCR4 antagonists, mobilizes HSCs to the peripheral blood77 and reduces ALL 
engraftment in animal models57,78. However, in mice suffering from ALL, CXCR4/CXCL12 
inhibition does not reduce the leukemic cell number in the BM78,79. This suggests that 
ALL cells use additional mechanisms to retain a protective microenvironment. Leukemic 
cells protected from chemotherapeutic treatment cause minimal residual disease, one 
of the most important predictors of patient outcome80-82. Discovering how ALL cells 
create a leukemic niche is crucial to develop more specific and effective ways to eliminate 
(residual) leukemic cells.
OUTLINE THESIS
Studies addressing the behavior of cancer cells and their similarities to stem cells have 
given new insights into improving treatment. HSCs are driven and maintained largely by 
their microenvironment and therefore it is likely that LSCs are also dependent on their 
niche. In the work described in this thesis, we aimed to identify novel mechanisms used 
by leukemic cells to create a leukemic niche. 
In Chapter 2 we describe the discovery of TNT signaling between BCP-ALL cells 
and MSCs, a crucial and abundant cell type in the BM. Confocal microscopy revealed 
high resolution images of TNTs connecting ALL cells and MSCs derived from patients. 
Signaling via TNTs was visualized by detecting the transfer of a lipophilic dye in ALL-MSC 
co-cultures. Finally, TNT signaling was inhibited to investigate its effect on the secretion 
of pro-survival factors and leukemic cell viability and drug resistance.
Currently, TNT signaling cannot be inhibited in patients. Since TNTs are cytoskeletal 
structures, we explored the effect of a large panel of actin and tubulin inhibitors for their 
potency in disrupting TNT signaling in Chapter 3. Until now, only actin polymerization 
has been shown to play a role in TNT signaling. In this chapter we investigated whether 
tubulin and actin nucleation and disassembly play similar roles. In addition, cytoskeletal 
inhibitors were screened for their effects on the viability of primary leukemic and healthy 
blood cells.
Chapter 4 investigated which structures are transported from ALL cells toward MSCs 
by detecting the transfer of ectopically expressed fluorescent marker proteins using 
flow cytometry. 
Migration and invasion of the BM microenvironment by BCP-ALL cells is the focus 
of Chapter 5. We modelled the leukemic niche using primary ALL-MSC co-cultures and 
used this to compare migration of healthy and leukemic cells. Importantly, we validated 
these experiments using serum derived from bone marrow aspirates of leukemia patients 
and healthy controls. These experiments show that the leukemic niche specifically attracts 
malignant cells independent of CXCR4/CXCL12 signaling and identify potential targets 
for leukemic niche disruption.
Finally, Chapter 6 discusses the impact of the findings in this thesis and offers 
perspectives for follow-up research.
Ligand-receptor
Gap junctions Tunneling nanotubes
Extracellular vesicles Soluble factors
Figure 1. Intercellular communication mechanisms
Figure 1. Intercellular communication mechanisms. Illustration summarizing how leukemic 
cells (green cells) might communicate with MSCs (grey cell). Cells express ligands on the plasma 
membrane which are detected by specialized receptors on the target cell, gap junctions exchange 
electrical signals, tunneling nanotubes connect nearby cells through an extension of the plasma 
membrane, extracellular vesicles are secreted and exchanged between distant cells, and multiple 
soluble factors are spread through the blood system.
MergedNALM6-DiO NALM6-DII
Figure 2. Tunneling nanotube formation between leukemic cells
Figure 2. Tunneling nanotube formation between leukemic cells. Confocal images showing 
TNT formation (white arrowhead) between two BCP-ALL cells (NALM6; DiI, yellow; DiO, green) after 
co-culture for 24 hours. White arrow indicates transfer of lipophilic structures to recipient cell.
LEUKEMIC CELL MIGRATION
One of the hallmarks of cancer cells is their ability to invade tissues7. In ALL, the BM 
is taken over by leukemic blasts that overgrow healthy cell types73. Much effort is put 
into finding targets that disrupt the migration of leukemic cells to clear these cells from 
the bone marrow. Migration of ALL cells toward the BM microenvironment is thought 
to be similar to that of HSCs. HSCs are attracted by CXCL12, a chemoattractant actively 
produced by MSCs in the BM.74-76 ALL cells, like HSCs, have high expression of the CXCL12 
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ABSTRACT
Acute lymphoblastic leukemia (ALL) cells reside in the bone marrow microenvironment 
which nurtures and protects cells from chemotherapeutic drugs. The disruption of cell-cell 
communication within the leukemic niche may offer an important new therapeutic 
strategy. Tunneling nanotubes (TNTs) have been described as a novel mode of intercellular 
communication, but their presence and importance in the leukemic niche are currently 
unknown. Here, we show for the first time that primary B-cell precursor ALL cells use TNTs 
to signal to primary mesenchymal stromal cells (MSCs). This signaling results in secretion 
of pro-survival cytokines, such as IP10/CXCL10, IL8 and MCP-1/CCL2. A combination 
of TNT disrupting conditions allows us to analyze the functional importance of TNTs in 
an ex vivo model. Our results indicate that TNT signaling is important for the viability 
of patient-derived B-cell precursor ALL cells and induces stroma-mediated prednisolone 
resistance. Disruption of TNTs significantly inhibits these leukemogenic processes and 
re-sensitizes B-cell precursor ALL cells to prednisolone. Our findings establish TNTs as 
a novel communication mechanism by which ALL cells modulate their bone marrow 
microenvironment. The identification of TNT signaling in ALL-MSC communication gives 
insight into the pathobiology of ALL and opens new avenues to develop more effective 
therapies that interfere with the leukemic niche.
KEY POINTS
Primary BCP-ALL cells use tunneling nanotubes to signal to mesenchymal stromal cells 
and thereby trigger cytokine secretion.
Inhibiting tunneling nanotube signaling is a promising approach to induce apoptosis and 
sensitize BCP-ALL cells towards prednisolone.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) cells reside in the local microenvironment of the bone 
marrow and are able to disrupt normal hematopoietic stem cell niches1. The disrupted, 
so called leukemic, niche is essential in initiating and facilitating leukemogenesis2-6. In 
addition, the leukemic niche protects leukemic cells from elimination by immune responses 
and chemotherapeutic agents, and can facilitate the development of drug resistance 
of leukemic cells7-10. Therefore, the disruption of the ALL-leukemic niche interaction 
offers a promising new therapeutic strategy11-16. However, it is still largely unclear how 
crosstalk occurs within the leukemic niche, and how this drives leukemic cell survival and 
chemotherapy resistance.
Recently, tunneling nanotubes (TNTs), or membrane nanotubes, have been described 
as a novel mode of communication between eukaryotic cells17-21. TNTs are thin membrane 
protrusions consisting of F-actin, that connect cells and facilitate the transport of several 
types of cargo, including organelles, pathogens, calcium fluxes, death signals, and 
membrane bound proteins19,20,22-24. These intercellular membrane conduits have been 
observed in several cell types, like cancer cells, complex tissues and organisms20,21,24-29. 
The pathophysiological importance of TNTs has become evident by studies showing that 
prions and HIV-1 particles use TNTs to promote disease spread21,30. However, the presence 
of TNTs within the leukemic niche and hence their role in communication between 
leukemic cells and the bone marrow microenvironment has not yet been addressed. Here, 
we study the role of TNT signaling in communication between primary B-cell precursor 
ALL (BCP-ALL) cells and MSCs and the contribution of TNT signaling to mesenchymal-
mediated survival and resistance to the chemotherapeutic drug prednisolone.
METHODS
Cell lines
BCP-ALL cell lines, NALM6 (B-Other) and REH (TEL-AML1), were obtained from DSMZ 
(Braunschweig, Germany). Only low cell passages were used, and the identity of cell lines 
was routinely verified by DNA fingerprinting. Immortalized hTERT-MSCs were a kind gift 
from Prof. Dr. D. Campana, St. Jude Children’s Hospital, Memphis, TN, USA.
Primary patient-derived material
Bone marrow aspirates were obtained from children with newly diagnosed BCP-ALL 
prior to treatment. Mononuclear leukemic cells were collected and processed as 
previously described31. All samples used in this study contained ≥97% leukemic blasts 
(supplemental Figure 7). Mesenchymal stromal cells (MSCs) were isolated from bone-
marrow aspirates obtained from newly diagnosed BCP-ALL patients (before treatment) 
and healthy controls. MSCs were processed as described previously32. Primary MSCs were 
characterized using positive (CD44/ CD90/ CD105/ CD54/ CD73/ CD146/ CD166/ STRO-1) 
and negative surface markers (CD19/ CD45/ CD34) (supplemental Figure 6). Multilineage 
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potential of MSCs was confirmed for adipocyte (Oil Red O staining), osteocyte (Alizarin 
Red S staining), and chondrocyte (Col2a/ Thionine/ Alcian Blue staining) differentiation.
Dye transfer experiments
Cells were stained with 1,1’-dioctadecyl-3,3,3’3’-tetramethylindocarbocyanine 
perchlorate (DiI; yellow), 3,3’-dioctadecyloxacarbocyanine (DiO; green), 1,1’-dioctadecyl-
3,3,3’3’-tetramethylindodicarbocyanine perchlorate (DiD; red), or Calcein red-orange AM 
(all from Life Technologies) according to the manufacturer’s protocol. Target populations 
were analyzed before and after co-culture with flow cytometry (BD Bioscience, San Jose, 
CA, USA) or confocal microscopy (see below).
Confocal laser scanning microscopy 
For high resolution images, differentially stained cells were cultured on a glass slide 
coated with 10 µg/mL fibronectin (Sigma) at 37 °C and 5% CO2. Cells were fixated 
as previously described33. Confocal images were acquired with sequential scanning of 
different channels at a resolution of 1024 x 1024 pixels in the x x y plane and 0.15 µm 
steps in z-direction (Leica SP5). For time-lapse confocal imaging, cultures were maintained 
at 37°C on a heated stage at 5% CO2 and images were acquired with sequential scanning 
of different channels at a resolution of 512 x 512 pixels in the x x y plane and 0.5 µm steps 
in z-direction. 3D image stacks were acquired by optical sectioning using the LAS software 
provided with the instrument. The system was equipped with a 63× plan-apochromat oil 
1.4 NA DIC objective. The pinhole diameter was set to 1 airy unit (95.5 μm). DiO and DiI 
were excited with a 488-nm Argon laser and a 561-nm Diode-Pumped Solid-State laser, 
respectively. Phalloidin-FITC (Sigma) was excited with the 488-nm Argon laser. Image 
processing was done with Fiji software34.
TNT inhibition
TNTs were inhibited using actin inhibition by latrunculin B (125 – 500 nM; Sigma) or 
cytochalasin D (250 nM – 1 µM; Sigma)20, by mechanical disruption via gentle shaking of 
cell cultures (250 rpm)21,35, or by physical separation of leukemic cells (cultured in a 3.0 
µm pore-sized insert) and MSCs (cultured in the bottom compartment of a transwell 
system; Corning, NY, USA)21,36. 
Cell viability assays
Primary patient cells (1 x 106 cells) were co-cultured with or without primary MSCs (5 
x 104) for five days in a 24-well plate at 37 °C and 5% CO2. The percentage of viable 
leukemic cells was determined by staining with Brilliant Violet 421 anti-human CD19 or 
CD45 antibody (Biolegend), FITC Annexin V (Biolegend), and Propidium Iodide (PI; Sigma), 
after which the percentage of AnnexinVneg/PIneg/CD19pos/CD45pos cells within the MSC 
negative fraction (see Figure 6A for gating strategy) was determined by flow cytometry 
(BD Biosciences). In supplemental Figure 10, viable leukemic cells were counted (PIneg/
CD19pos) using a MACSQuant analyzer (Miltenyi Biotec, Gladbach, Germany).
Multiplexed fluorescent bead-based immunoassay (Luminex)
Primary leukemic cells and leukemic cell lines were co-cultured with primary MSCs with 
or without TNT inhibition (shaking or transwell condition) for indicated time points at 
37 °C and 5% CO2. Next, the supernatant was collected and cell viability of leukemic 
cells was assessed as described above. The concentration of 64 cytokines/chemokines 
in supernatants of ALL-MSC co-cultures was analyzed using a fluorescent bead-based 
immunoassay (Luminex Human Cytokine/Chemokine Panel I and II; Merck Millipore) 
according to the manufacturer’s protocol. 
Statistical analysis
Student’s t-test was used as a statistical test and a Student’s paired t-test was used when 
applicable (indicated in figure legends). Bar graphs represent the mean of biological 
replicates. Error bars show as standard error of the mean (SEM).
RESULTS
BCP-ALL cells use TNTs to effectively signal to MSCs
TNT formation within the hematopoietic niche was studied by confocal microscopy and 
flow cytometry. TNTs are thin membrane tethers and can be visualized using lipophilic 
carbocyanine dyes20,21. These dyes stain lipophilic structures in the entire cell, and exhibit 
very low cell toxicity, while passive transfer of these dyes is negligible. Therefore, these dyes 
are widely used in live cell tracking experiments1,37. Interestingly, it has been shown that 
organelles and membrane components stained by these dyes can be actively transported 
via TNTs20. Therefore, these dyes were used to visualize intercellular communication via 
TNTs within the leukemic niche. 
Differential staining of NALM6 BCP-ALL cells (stained with DiI-yellow) and 
mesenchymal stromal cells (hTERT-MSCs; stained with DiO-green) revealed that TNTs 
were formed within 3 hours of co-culture (Figure 1A, supplemental Figure 1M-P). 3D 
reconstruction of these images shows that nanotubular structures between cells do not 
connect with the substratum (i.e. the fibronectin-coated glass slide; see supplemental 
Video 1A-B and supplemental Video 2). As expected, staining with Phalloidin-FITC shows 
the presence of F-Actin filaments in these nanotubular structures (see supplemental 
Figure 1Q-R). Importantly, bidirectional transfer of lipophilic dyes was observed, 
indicating active crosstalk within the leukemic niche (Figure 1A). Besides formation of 
TNTs between leukemic cells and MSCs,  TNT networks and transfer of lipophilic dye was 
also observed in mono-cultures of BCP-ALL cells and MSCs (supplemental Figure 1A-L and 
supplemental Figure 2).
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In order to quantify active crosstalk via TNTs we used flow cytometrical analysis of 
dye transfer from labeled donor cells to unlabeled recipient cells. CD19-positive BCP-ALL 
cell lines (NALM6 and REH) were stained with lipophilic dye DiI and co-cultured with 
unstained CD19-negative hTERT-MSCs (supplemental Figure 3A-C for gating strategy). 
After 6 hours of culture, more than 50% of the MSCs were positive for DiI. This number 
increased to >85% after 24 hours, highlighting the efficient dye transfer from leukemic 
cells to MSCs (Figure 1B and supplemental Figure 3D). In reciprocal experiments we also 
observed dye transfer from MSCs to BCP-ALL cells, but the magnitude of dye transfer 
was strikingly less than from ALL cells towards MSCs (175-fold, p-value ≤ 0.001) 
(Figure 1C-D).
Transfer of lipophilic dyes can be mediated by several processes including TNT 
signaling and signaling via extracellular vesicles (ECV). To evaluate the contribution of TNT 
signaling to the observed lipophilic dye transfer between leukemic cells and MSCs, we 
inhibited TNTs using three independent experimental setups: 1) reducing TNT formation 
through actin inhibition20, 2) mechanical disruption of TNT connections through gentle 
shaking of cell cultures21,35, and 3) prevention of TNT formation by physically separating 
leukemic cells (cultured in a 3.0 µm pore-sized insert) and MSCs (cultured in the bottom 
compartment of a transwell system)21,36. 
For inhibition of the polymerized F-actin of which TNTs are composed20, we used two 
classes of F-actin polymerization inhibitors: cytochalasin D and latrunculin B. In addition 
to F-actin elements, TNTs need prolonged cell contact to signal efficiently. Gentle shaking 
of ALL-MSC co-cultures reduces the lifespan of TNTs, while direct contact between 
Figure 1. TNT signaling between BCP-ALL cells and MSCs. (A) Representative confocal images 
(Z-stack) showing TNT networks (white arrowheads) between BCP-ALL cell line REH (DiI, yellow) 
and hTERT-immortalized MSCs (DiO, green) after co-culture for 3 hours. Bidirectional exchange of 
lipophilic dye via TNTs was observed (green arrow for MSC to ALL, yellow arrow for ALL to MSC). 
Leukemic cells also formed TNT-like structures towards the fibronectin-coated substratum (orange 
arrowhead). (B) Graph showing quantification of dye transfer from DiI-stained NALM6 cells towards 
unstained hTERT-MSCs (cultured in 4:1 ratio) in time. Figure shows representative experiment 
(n = 3). (C) Graph showing quantification of dye transfer after 24 hours of co-culture (cultured in 
1:1 ratio). Left panel shows dye transfer from DiI-stained hTERT-MSCs towards unstained NALM6 
cells. Right panel shows the reciprocal experiment (also performed in a 1:1 ratio). White and grey 
histograms represent staining intensity at the start of each experiment. (D) Quantification of dye 
transfer in time of experiment as exemplified in (C), performed with two different BCP-ALL cell lines 
(REH and NALM6). Dye transfer from MSCs towards ALL was compared to dye transfer from ALL 
towards MSCs (n = 4; two-tailed t-test, unpaired). (E) Graph showing quantification of dye transfer 
from DiI-stained NALM6 cells towards unstained hTERT-MSCs with (red histograms) or without 
(grey histograms) TNT inhibition. Cells were co-cultured in 4:1 ratio for 6 hours. Three independent 
TNT inhibiting conditions were used: actin inhibition by cytochalasin D or latrunculin B, physical 
disruption by gentle shaking, or culture in a 3.0 μm transwell system. (F) Quantification of dye 
transfer experiment exemplified in (E), performed with two different BCP-ALL cell lines (REH and 
NALM6) (n = 4; one-tailed t-test, unpaired).  Data are means ± SEM; ** p ≤ 0.01, *** p ≤ 0.001. 
See also supplemental Figures 1 and 3, and supplemental Videos 1A-B and 2.
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BCP-ALL cells and MSCs is still possible. However, it is well established in literature 
that flow-derived shear forces (gentle shaking) induce integrin-mediated signaling38,39. 
Therefore, we also physically separate ALL cells and MSCs using a transwell system, to 
exclude the effects of increased integrin signaling. We used a 3.0 µm transwell system to 
investigate the contribution of extracellular vesicle signaling to lipophilic dye transfer. In 
this transwell system leukemic cells are physically separated from MSCs, while exchange 
of extracellular vesicles (30-1000 nm) is still possible.
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Cytochalasin D and latrunculin B both caused a dose-dependent reduction of dye 
transfer after 6 hours of co-culture (p ≤ 0.01; Figure 1E-F and supplemental Figure 3E-F). 
Due to the short half-time of these actin inhibitors40,41, TNT formation was restored within 
24 hours (supplemental Figure 3E-F). Disruption of TNT structures by gentle shaking 
reduced dye transfer by more than 5-fold (p  ≤  0.01; Figure 1E-F and supplemental 
Figure 3G). Importantly, dye transfer from BCP-ALL cell lines to MSCs was nearly absent 
in transwell experiments (p ≤ 0.001), which indicates that dye transfer occurs mainly via 
TNTs and not via extracellular vesicles (Figure 1E-F and supplemental Figure 3H). 
The TNT forming capacity was also evaluated in an ex vivo niche model using leukemic 
cells and MSCs that were both freshly obtained from patients with newly diagnosed 
BCP-ALL (Figure 2A, supplemental Figure 4A-J, supplemental Figure 5A-D, supplemental 
Figure 6 and supplemental Figure 7).  Ex vivo co-cultures revealed that TNTs rapidly (< 3 
hours) form between primary BCP-ALL cells and primary MSCs, and efficiently transfer 
lipophilic dye (Figure 2B, supplemental Figure 4G-J, supplemental Figure 5). The source of 
MSC did not affect the efficacy of TNT signaling. Dye transfer was similarly efficient from 
ALL cells towards 10 different primary MSCs (n = 5 healthy and n = 5 leukemic primary 
patient-derived MSCs; Figure 2C-D and supplemental Figure 8A-C).
The dynamics of TNT formation between BCP-ALL cells and MSCs were investigated 
using time-lapse confocal microscopy. Leukemic cells initiated formation of TNTs and 
transferred lipophilic dye towards MSCs within minutes (Figure 3A; supplemental 
Videos 3 and 4A). Leukemic cells were able to form multiple TNTs and signal to several 
MSCs simultaneously (Figure 3B; and supplemental Videos 3 and 4A-B). TNTs formed 
between MSCs and leukemic cells were stable for multiple hours and could reach several 
cell diameters in length (Figure 3C, supplemental Videos 3 and 4A). After 10 hours, 
the majority of MSCs became DiI-positive (supplemental Videos 3 and 4B), as confirmed 
by flow cytometry (Figure 1B).
TNTs are important players in signaling from BCP-ALL cells to MSCs
The above-mentioned findings suggest that TNT signaling is a highly effective 
communication mechanism between ALL cells and MSCs. This was further illustrated 
by comparing TNT signaling to other intercellular communication mechanisms, 
including gap junctions, integrins and ECV (Figure 4A). Dye transfer from leukemic cells 
towards MSCs was minimal using a 3.0 µm transwell system, in which ECV signaling is 
possible (> 500 fold lower compared to normal co-culture after 24 hours; p ≤ 0.001; 
Figure 4B-C). Transfer experiments with the gap junction-specific dye Calcein revealed 
that signaling from leukemic cells towards primary MSCs via gap junctions is highly 
ineffective compared to signaling via TNTs (> 90 fold lower after 24 hours; p ≤ 0.001; 
Figure 4D-E). Integrin signaling has been implicated in the induction of TNTs42, raising 
the question whether TNTs function autonomously or in an integrin-dependent manner. 
To inhibit integrin signaling between BCP-ALL cells and MSCs, we used RGDS-peptides, 
reported to prevent the binding of integrins to membranes43. RGDS negatively affected 
Figure 2. Primary BCP-ALL cells signal to MSCs via TNTs. (A) Representative confocal images 
(Z-stack) showing TNT formation (white arrowhead) between a primary CD34-positive cell (DiI, 
yellow) and a hTERT-immortalized MSC (DiO, green) after co-culture for 3 hours. White arrow 
indicates transfer of dye to recipient cell. (B) Graphs showing quantification of dye transfer in 
co-cultures of BCP-ALL patient cells with primary MSCs (cultured in 4:1 ratio). Inhibition of TNTs 
was performed by gentle shaking of co-cultures, or co-culture in a 3.0 μm transwell system (red 
histograms). (C) Graphs showing quantification of dye transfer from DiI-stained NALM6 cells towards 
10 different unstained primary MSCs (cultured in 4:1 ratio) obtained from leukemia patients (n = 
5) and healthy controls (n = 5). (D) Graphs showing quantification of dye transfer from DiI-stained 
NALM6 cells towards 3 different primary MSCs with (red histograms) or without (grey histograms) 
TNT inhibition. See also supplemental Figures 4-8.
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the efficiency of lipophilic dye transfer via TNTs whereas the transfer in the presence of 
negative control peptides (GRADSP) remained unaffected (Figure 4F). The reduction in 
lipophilic dye transfer was limited to a maximum of 30% (p ≤ 0.01). Taken together, 
these data reveal that TNT signaling acts independently of other important intercellular 
communication mechanisms, i.e. signaling via extracellular vesicles, gap junctions, 
and integrins.
BCP-ALL cells use TNTs to drive cytokine release within  
the microenvironment
The question remains how TNT signaling from leukemic cells affect their microenvironment. 
Since cytokines and chemokines can greatly affect the survival of leukemic cells44,45, we 
considered that the microenvironment responds to TNT signaling by secreting supportive 
soluble factors. Therefore we investigated the secreted levels of 64 known cytokines/
chemokines in co-cultures of primary leukemic cells of two BCP-ALL patients with 
different sources of primary MSCs. Co-culture of these cells induced the secretion of 
several cytokines. The cytokine signature produced within co-cultures suggested that 
this secretion was leukemia-driven and independent of the MSC source (Figure 5). IP10/
CXCL10 levels increased more than 1000-fold when patient ALL#7 cells were co-cultured 
with MSCs, but were undetectable in co-cultures from patient ALL#9 cells (Figure 5A and 
5E). Likewise, MDC/CCL22 and TARC/CCL17, both undetectable in patient ALL#7 co-
cultures, were induced 6-18 fold when patient ALL#9 cells were co-cultured with MSCs 
(Figure 5C-D and 5G-H). Interleukin-8 (IL8) levels were induced (2-7 fold) by primary ALL 
cells from both patients (Figure 5B and 5F). Cytokines that were induced less than 2 fold 
in co-culture are shown in supplemental Figure 9. Only a limited number of cytokines/
chemokines were found to be significantly upregulated in patients’ ALL-MSC co-cultures 
compared to mono-cultures of both cell types. Also in a proliferative setting (using 
the BCP-ALL cell line NALM6), a limited number of known cytokines were upregulated 
in co-culture with two different primary MSCs: IL8 and VEGF levels were on average 
induced 2 and 3 fold respectively (n=3, p ≤ 0.01, Supplemental Figure 9E-H). These MSC-
independent and leukemia-consistent cytokine signatures suggest that leukemic cells, 
and not MSCs, are responsible for the active modulation of the tumor microenvironment. 
Induction of the observed cytokines was dependent on TNT signaling, as TNT inhibition 
significantly lowered the secreted levels of these factors (Figure 5A-H, Supplemental 
Figure 9E-H). However, TNT inhibition only partly reversed the induction of cytokine 
levels in ALL-MSC co-cultures, suggesting that, next to TNT signaling, other intercellular 
signaling routes contribute to the induction of these secretomes. 
TNT signaling is important for the survival of primary BCP-ALL cells
Several studies have shown the importance of the microenvironment for the survival 
of malignant cells, but without elucidating how46. In order to study the effect of TNT 
signaling on leukemic cell viability, we used ex vivo co-cultures of primary BCP-ALL cells 
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Figure 3. Dynamic nature of TNT formation between BCP-ALL cells and MSCs.
Figure 3. Dynamic nature of TNT formation between BCP-ALL cells and MSCs. (A-C) Time-
lapse confocal images (3D image stacks) showing TNT formation (white arrowhead) between 
NALM6 cells (DiI, yellow) and  primary MSCs at multiple time points. White arrow indicates transfer 
of dye to recipient cell. Time indicated in the right lower corner is the duration from start of 
the experiment. Orange Hot look-up table (LUT) and transmission overlays were used to illustrate 
dye transfer towards MSCs. Scale bars represent 10 µm. (A and C) Depicted images are close-ups of 
the upper left corner of supplemental Video 3. (B) Depicted images are close-ups of supplemental 
Video 4A. Data is representative of three independent experiments. See also supplemental Figure 5 
and supplemental Videos 3 and 4A-B. 
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Figure 4. TNTs are important players in signaling from BCP-ALL cells to MSCs. (A) Model 
of crosstalk between leukemic cells and MSCs in the hematopoietic niche. (B) Graphs showing 
quantification of dye transfer from DiI-stained NALM6 cells towards unstained hTERT-MSCs. Blue 
and grey histograms represent staining intensity at the start of each experiment. Red histogram 
represents signaling efficiency via TNTs (normal co-culture; left panel) and via extracellular vesicles 
(ECV) (3.0 μm transwell; right panel). (C) Bar graphs of experiment shown in (B) after 6 hours (left 
panel) and 24 hours (right panel) of co-culture (n = 4; two-tailed t-test, unpaired). (D) Graphs 
showing quantification of dye transfer from BCP-ALL cell line NALM6, stained with either DiI or 
calcein, towards primary MSCs after 24 hours of co-culture. Blue and grey histograms represent 
staining intensity at the start of each experiment. Red histogram shows signaling efficiency via TNTs 
(left panel) and via gap junctions (right panel). (E) Bar graphs of experiment shown in (D) after 8 
hours (n = 6; left panel) and 24 hours (n = 4; right panel) of co-culture (two-tailed t-test, unpaired). 
(F) Bar graphs representing dye transfer from DiI-stained REH cells towards unstained primary MSCs 
with and without integrin blocking. Integrin signaling was blocked by addition of RGDS peptide, 
and compared to addition of the integrin non-binding peptide GRADSP (n = 5; one-tailed t-test, 
paired). Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Figure 5. BCP-ALL cells use TNTs to drive cytokine release within the microenvironment. (A) 
IP10/CXCL10 supernatant levels in co-culture of primary leukemic patient ALL#7 cells with primary 
MSC#1 (left panel), MSC#2 (middle panel), or MSC#3 (right panel). TNT signaling was inhibited 
by gentle shaking or culture in a transwell system (one-tailed t-test, unpaired). (B) Same as (A) for 
IL8 levels. (C) Same as (A) for MDC (CCL22) levels. (D) Same as (A) for TARC (CCL17) levels. (E) 
IP10/CXCL10 supernatant levels in co-culture of primary leukemic patient ALL#9 cells with primary 
MSC#4 (left panel), or MSC#5 (right panel). (F) Same as (E) for IL8 levels. (G) Same as (E) for MDC 
(CCL22) levels. (H) Same as (E) for TARC (CCL17) levels. Data are means ± SEM; * p ≤ 0.05, ** p ≤ 
0.01. nd = not detectable (below detection level). See also supplemental Figure 9.
0
500
1000
1500
2000
pg
/m
L
pMSC#1
IP10 (CXCL10)
0
1000
2000
3000
4000
***
***
***
***
0
2000
4000
6000
***
***
0
1000
2000
3000
4000
5000
pg
/m
L
IL8
**
**
0
500
1000
1500
2000
**
*
0
500
1000
1500
*
**
Co-culture
A
B
 
Patient ALL#7
IL8
MDC (CCL22)
0
500
1000
1500
pg
/m
L
0
200
400
600
800
**
**
**
***
0
100
200
300
400
500
0
100
200
300
400
500
pg
/m
L
**
*
**
**
***
**
***
**
0
10
20
30
40
pg
/m
L
0
5
10
15
20
TARC (CCL17)    
E
F
G
H
Patient ALL#9
Co-cultureMono Co-culture
Co-culture Co-culture
Mono Mono
Mono Mono
Figure 5. BCP-ALL cells use TNTs to drive cytokine release within the microenvironment 
pg
/m
L
Co-cultureMono
Below detection level 
Co-cultureMono
IP10 (CXCL10) 
C
pg
/m
L
MDC (CCL22)      
D
pg
/m
L
TARC (CCL17)      
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
pMSC#2 pMSC#3 pMSC#4 pMSC#5
nd nd nd nd nd nd
ndnd
ndnd
Below detection level 
Below detection level Below detection level Below detection level 
Below detection level Below detection level Below detection level 
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Co-cultureCo-cultureMono Co-cultureMono Mono Co-cultureMono Co-cultureMono
Co-cultureCo-cultureMono Co-cultureMono Mono Co-cultureMono Co-cultureMono
0
500
1000
1500
2000
pg
/m
L
pMSC#1
IP10 (CXCL10)
0
1000
2000
3000
4000
***
***
***
***
0
2000
4000
6000
***
***
0
1000
2000
3000
4000
5000
pg
/m
L
IL8
**
**
0
500
1000
1500
2000
**
*
0
500
1000
1500
*
**
Co-culture
A
B
 
Patient ALL#7
IL8
MDC (CCL22)
0
500
1000
1500
pg
/m
L
0
200
400
600
800
**
**
**
***
0
100
200
300
400
500
0
100
200
300
400
500
pg
/m
L
**
*
**
**
***
**
***
**
0
10
20
30
40
pg
/m
L
0
5
10
15
20
TARC (CCL17)    
E
F
G
H
Patient ALL#9
Co-cultureMono Co-culture
C -culture Co-culture
Mono Mono
Mono Mono
Figure 5. BCP-ALL cells use TNTs to drive cytokine rel ase within e microenvironme t 
pg
/m
L
Co-cultureMono
Below detection l vel 
Co-cultureMono
IP10 (CXCL10) 
C
pg
/m
L
MDC (CCL22)      
D
pg
/m
L
TARC (CCL17)      
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
pMSC#2 pMSC#3 pMSC#4 pMSC#5
nd nd nd nd nd nd
ndnd
ndnd
Below detection l vel 
Below detection l vel Below detection l vel Below detection l vel 
Below detection l vel Below detection l vel Below detection l vel 
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
7
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Tr
an
sw
ell
AL
L#
9
Sh
ak
ing
No
rm
al
MS
C
Co-cultureCo-cultureMono Co-cultureMono Mono Co-cultureMono Co-cultureMono
Co-cultureCo-cultureMono Co-cultureMono Mono Co-cultureMono C -cultureMono
A
LL C
ELLS U
SE TN
TS TO
 O
RC
H
ESTRA
TE TH
EIR M
IC
RO
EN
V
IRO
N
M
EN
T
34 35
22
A
LL C
ELLS U
SE TN
TS TO
 O
RC
H
ESTRA
TE TH
EIR M
IC
RO
EN
V
IRO
N
M
EN
T
and primary MSCs (see table S1 for BCP-ALL subtype information, Figure 6A for gating 
strategy). Primary BCP-ALL cell survival significantly increased in 5-day co-cultures with 
primary MSCs compared to mono-cultures. When TNT formation was prevented by 
shaking of co-cultures or by transwell conditions, this increase significantly reduced 3.5- 
and 3.6-fold, respectively (n = 7, p ≤ 0.001; Figure 6B-D). The effect of TNT inhibition 
was consistent across leukemic cells from multiple cytogenetic BCP-ALL subgroups 
 (TEL-AML1, BCR-ABL1-like, and B-Other). 
Inhibition of TNTs sensitizes BCP-ALL cells to prednisolone
We investigated whether inhibition of TNT signaling also affects the response of 
leukemic cells to chemotherapeutic drugs. BCP-ALL patient cells were treated with 
the ALL spearhead drug prednisolone for 5 days. Prednisolone was less effective in 
inducing apoptosis of primary BCP-ALL cells in the presence of primary MSCs compared 
to mono-cultures of primary BCP-ALL cells (70% vs 5% reduced viability; p ≥ 0.001; 
Figure 7A), underlining the importance of MSCs in the induction of prednisolone 
resistance (Figure 7A). The protective effect of MSCs was significantly reduced by 2-3 
fold (n = 4, p  ≤  0.001; Figure 7A) when TNT signaling was inhibited. TNT inhibition 
alone was not sufficient to abrogate all microenvironment-induced drug resistance. In 
shaking and transwell conditions, which allow signaling via integrins, soluble factors 
or ECVs, microenvironment-induced resistance to prednisolone was still present 
(p ≥ 0.01). Since ex vivo cultured leukemic patient cells lose their propensity to proliferate, 
we also addressed the effect of TNT signaling on drug resistance in a proliferative 
setting using the BCP-ALL cell line NALM6. Similar to primary BCP-ALL cells, co-culture 
with MSCs induced prednisolone resistance of NALM6 cells (Figure 7B). Inhibition of 
TNT formation by shaking of co-cultures or transwell conditions significantly reduced 
this effect 4.5- and 8.5- fold, respectively (p ≤ 0.01; Figure 7B and supplemental Figure 
10A-B). These data show that inhibition of TNT signaling in co-cultures sensitizes BCP-ALL 
cells to the anti-leukemic effects of prednisolone in both a primary non-proliferative and 
a proliferative setting.
DISCUSSION
The presented study identifies TNT formation as a novel regulator of interaction 
between BCP-ALL cells and their bone marrow niche, which facilitates signaling from 
leukemic cells towards MSCs and affects the release of cytokines and chemokines in 
the microenvironment. Disruption of TNTs inhibits this release, decreases the survival 
benefit that MSCs provide to primary BCP-ALL cells, and sensitizes BCP-ALL cells to 
the important anti-leukemic drug prednisolone (supplemental Figure 11).
Relapse of leukemia is caused by a small number of leukemic cells that are able 
to withstand chemotherapy and can cause the complete reconstitution of the tumor. 
Leukemogenic mouse models show the importance of signaling between leukemic 
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Figure 6. TNT signaling is important for the survival of primary BCP-ALL cells. (A) Flow chart 
and flow cytometrical gating strategy used to study the effect of TNTs on BCP-ALL cell survival. Co-
cultures of CD19positive leukemic cells and CD19negative MSCs were stained with Brilliant Violet 421™ 
anti-human CD19 antibody, FITC Annexin V, and Propidium Iodide (PI). MSCs were excluded (red 
gate), and the percentage of viable BCP-ALL blasts (AnnexinVneg/PIneg/CD19pos cells) was determined 
within the MSC-negative fraction. (B) Percentage of viable primary leukemic patient cells (n = 3 
TEL-AML1, n = 2 B-Other, n = 2 BCR-ABL1-like) in mono-culture (black bars) or co-culture with 
patient MSCs (white bars) after 5-day co-culture. (C) The survival benefit for primary leukemic 
patient cells (n = 3 TEL-AML1, n = 2 B-Other, n = 2 BCR-ABL1-like) in co-culture with patient MSCs. 
(D) The mean survival benefit for primary leukemic patient cells in co-culture with patient MSCs 
(n = 7; one-tailed t-test, paired). Data are means ± SEM; *** p ≤ 0.001.
cells and their bone marrow microenvironment and emphasize the pathophysiological 
relevance of cytokines within the leukemic niche1,47-49. However, a major shortcoming 
in our knowledge about the leukemic niche is the lack of insight into the functional 
mechanism mediating crosstalk between leukemic cells and their local niche. Our data 
adds significant insight into this process and provides an opportunity to inhibit the leukemic 
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niche. Importantly, primary BCP-ALL cells use TNTs to modulate their microenvironment, 
identifying the leukemic cell, and not MSCs, as the driver of niche modulation. 
Although less pronounced as seen between ALL cells and MSCs, TNTs are also used for 
communication between leukemic cells. This discovery may reveal a new aspect of tumor 
heterogeneity. In many cancer types, clonal evolution has been observed50. A recent study 
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Figure 7. Inhibition of TNTs sensitizes BCP-ALL cells to prednisolone. (A) Leukemic cell survival 
of patient ALL#6 cells cultured with or without MSCs after 5 days of prednisolone exposure (0.3 
µg/mL). All graphs show percentage compared to untreated control. TNT signaling was inhibited 
by shaking or transwell conditions (one-tailed t-test, unpaired). Quadruplicates represent four 
different sources of MSCs (MSC#1, MSC#2, MSC#6, MSC#7). (B) Leukemic cell survival of BCP-ALL 
cell line NALM6 cultured with or without MSCs after 5 days of prednisolone exposure. All graphs 
show percentage compared to untreated control. TNT signaling was inhibited by shaking or 
transwell conditions (one-tailed t-test, unpaired). Triplicates represent three different sources of 
MSCs (hTERT, MSC#1, and MSC#2). Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01. See also 
supplemental Figure 10.
in T-ALL by Blackburn et al. shows that leukemia subclones acquire mutations, that can 
mediate chemotherapy resistance even without prior drug exposure51. Leukemic cells 
might exploit TNTs, which can transfer a broad spectrum of molecules and organelles like 
membrane-associated signaling molecules (e.g. H-Ras19), to transfer mutant proteins and 
subsequently chemotherapy resistance between subclones.
Several studies report that the leukemic niche can induce drug resistance for both 
classical chemotherapeutic agents and newly developed targeted therapies9,44-46,52-54. 
The seminal papers by Strausmann et al, and Wilson et al. revealed the widespread potential 
for growth-factor-driven resistance to kinase inhibitors in several tumor types. A recent 
study by Manshouri et al., showed the induction of resistance against JAK2 inhibitors by 
bone marrow stroma-secreted cytokines in JAK2-mutated primary hematopoietic cells. 
BCP-ALL cells use TNTs to induce a pro-inflammatory cytokine signature within their 
microenvironment55. These cytokines have been reported to be involved in leukemia 
survival and resistance to therapy, like IP10/CXCL1054, IL-856, and MCP-1/CCL257. When 
TNTs were inhibited, this signature was partly reversed and simultaneously leukemic cell 
survival was decreased. Since these cytokines also have a chemoattractive function, it is 
likely that migration towards the stromal compartments of the niche and subsequent 
induction of contact-dependent signaling modules, like integrins and gap junctions, 
also play a role in this process. Further, we observed TNT signaling from MSCs towards 
leukemic cells, which might also influence drug resistance of leukemic cells. For example, 
TNTs have been shown to transport drug-efflux pumps such as P-glycoproteins24, and to 
transport mitochondria preferentially towards cancer cells28. 
Interestingly, we observed leukemia-specific cytokine patterns in MSC-ALL co-cultures 
that were affected by abrogation of TNT signaling. This observation opens the discussion 
how TNT signaling can lead to the upregulation of different soluble factors. The broad 
spectrum of signaling molecules that are transported by TNTs potentially allows the ALL to 
convey specific messages to MSCs in order to differentially regulate the secretion of soluble 
factors by its microenvironment. In addition, leukemia is a highly heterogeneous disease 
consisting of different (cyto)genetic subtypes that also have individual heterogeneity with 
regards to their transcriptome and proteome58. These factors are all likely to contribute to 
leukemia-unique demands for microenvironmental support.
Targeting TNT-directed communication between leukemic cells and their supportive 
niche may be a promising new approach to kill leukemic cells and prevent drug resistance 
in clinical practice. As of yet, no agents are available that induce specific inhibition of TNT 
signaling, but our data point to the importance to develop such agents. TNT signaling 
can be disrupted through shear stress, applying a physical distance between the cells, 
actin inhibition, and in some cases tubulin inhibition. In additional experiments, we 
observed that tubulin inhibition did not inhibit TNT signaling between BCP-ALL cells and 
MSCs (data not shown). The common building block for all TNTs reported in literature 
is F-actin, making it an obvious target for TNT disruption. Actin inhibitors are derived 
from fungi, plants and sponges, which developed these toxins as a defense mechanism. 
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Consequently, these compounds inhibit TNT formation (Figure 1E-F) and induce cell death 
(data not shown). Therefore, it is important to develop more specific and less-toxic small 
molecule inhibitors that target elements of the actin cytoskeleton important for TNT 
formation. We propose our primary patient-derived ex vivo model system as a highly 
suitable platform to identify such inhibitors. Once identified, these TNT-specific agents 
will allow us to investigate TNT signaling also in vivo.  
In conclusion, the discovery of TNT signaling between BCP-ALL cells and mesenchymal 
stromal cells adds significant insight into the mechanisms of communication in the leukemic 
niche. BCP-ALL cells use TNT networks to modify their healthy microenvironment and 
hereby create a leukemic niche that induces survival and drug resistance. Current 
chemotherapeutic regimens are primarily focused on combating tumor intrinsic properties. 
Our data provide a new concept to develop alternative therapeutic strategies that include 
targeting of the leukemic niche in B-cell acute lymphoblastic leukemia.
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SUPPLEMENTAL TABLES
Supplemental Table 1. Characteristics of primary BCP-ALL cells
Name Subtype Remarks
ALL#1 BCR-ABL1 -
ALL#2 TEL-AML1 -
ALL#3 TEL-AML1 -
ALL#4 TEL-AML1 -
ALL#5 B-Other E2A-rearranged subclone (21%)
ALL#6 B-Other -
ALL#7 BCR-ABL1-like -
ALL#8 BCR-ABL1-like Down syndrome
ALL#9 BCR-ABL1-like -
ALL#10 B-Other ETV6 loss
Supplemental Table 2. Characteristics of primary MSCs
Name Subtype Remarks
MSC#1 B-Other -
MSC#2 TEL-AML1 -
MSC#3 B-Other -
MSC#4 Remission 1 year after treatment
MSC#5 AML -
MSC#6 Healthy -
MSC#7 Healthy -
MSC#8 Healthy -
MSC#9 Healthy -
MSC#10 Healthy -
MSC#11 B-Other -
MSC#12 TEL-AML1 -
MSC#13 CML -
Supplemental Table 3. Cytokine secretion in mono and co-cultures of ALL and MSCs
Cytokine MSCs ALL Co-culture
6Ckine
BCA-1
CTACK
EGF x x
ENA-78
Eotaxin x
Eotaxin-2
Eotaxin-3 x
FGF-2 x
Flt3 Ligand
Fractalkine
G-CSF
GM-CSF x
GRO x
I-309
IFNalpha2
IFNgamma
IL10
IL12
p70
IL13
IL15
IL16
IL17A
IL1alpha
IL1beta
IL1-ra
IL2
IL20
IL21
IL23
IL28a
IL3
IL33
IL4
IL5
IL6 x
IL7
IL8 x x x
IL9
IP10 x
LIF
MCP-1 x x
A
LL C
ELLS U
SE TN
TS TO
 O
RC
H
ESTRA
TE TH
EIR M
IC
RO
EN
V
IRO
N
M
EN
T
44 45
22
A
LL C
ELLS U
SE TN
TS TO
 O
RC
H
ESTRA
TE TH
EIR M
IC
RO
EN
V
IRO
N
M
EN
T
Supplemental Table 3. (continue)
Cytokine MSCs ALL Co-culture
MCP-2
MCP-3
MCP-4
MDC x
MIP-1alpha x
MIP-1beta x
MIP-1delta
PDGF-AA x x
PDGF-BB x
RANTES
sCD40L
SCF x
SDF1-alpha/beta x
TARC x
TGFalpha
TNFalpha x
TNFbeta
TPO
TRAIL
TSLP
VEGF x x x
Supplemental Figure 1. TNTs between BCP-ALL cells and MSCs. (A-H) Interleukemic TNT 
networks (exemplified by white arrowheads) and exchange of lipophilic dye (exemplified by arrows) 
between NALM6 (A-D) or REH (E-H) cells (DiI, yellow; DiO, green) were observed after 24 hours of 
co-culture. White arrows indicate transfer of dye to recipient cell. (I-L) TNT networks were formed 
and dye transfer was present between hTERT-immortalized MSCs (DiI, yellow; DiO, green). TNT-like 
structures also attached to the fibronectin-coated substratum (exemplified by orange arrowheads; 
right panel). Red arrowheads (left panel) represent ‘midbodies’. These midbodies look similar to 
TNTs, but are a short-lasting remainder of cell division. (M-P) Co-cultures of hTERT-immortalized 
MSCs (indicated by MSC) and BCP-ALL cell line NALM6 (indicated by LC) showed elaborate TNT 
networks and dye transfer after 3 hours of co-culture. (Q-R) Phalloidin-FITC staining of F-actin, 
shows the presence of F-Actin in TNTs between BCP-ALL cells (NALM6) and MSCs (primary MSC#1). 
White arrowheads indicate TNTs. DAPI-staining (blue) was used to stain nuclei. Images M-P are 3D 
image stacks. Scale bars represent 10 µm.
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Supplemental Figure 2. TNT signaling between BCP-ALL cells. (A) Representative confocal 
images showing TNT formation (white arrowhead) between two NALM6 cells (DiI, yellow; DiO, 
green) after co-culture for 24 hours. White arrow indicates transfer of dye to recipient cell. (B) DiD-
stained BCP-ALL NALM6 cells were cultured in a 1:1 ratio with DiO-stained BCP-ALL NALM6 cells for 
24 hours. Double positive cells (DiD+/DiO+) were quantified and used as a measure of interleukemic 
signaling. Right panel represents the start of the experiment. (C) Graphs showing quantification 
of interleukemic dye transfer between NALM6 cells. Gentle shaking reduced interleukemic TNT 
signaling whereas culture in a 3.0 μm transwell system – in which leukemic cells reside in close 
contact - increased interleukemic TNT signaling. (D) Bar graphs representing interleukemic dye 
transfer in TNT-inhibiting and TNT-inducing conditions, exemplified in (C), compared to dye transfer 
in normal co-culture (n = 4; one-tailed t-test, paired). Data are means ± SEM; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001.
Supplemental Figure 3. Lipophilic dye transfer is caused by TNT signaling. DiI-stained CD19pos 
BCP-ALL cells (NALM6 and REH) were co-cultured with unstained CD19neg hTERT-MSCs and transfer 
of DiI staining to hTERT-MSCs was analyzed by flow cytometry at the indicated time points. (A-C) 
Gating strategy for analysis of dye transfer from leukemic cells towards MSCs. Panel C represents 
the start of the experiment. (D) Quantification of dye transfer showing efficient transfer from DiI-
stained REH cells towards unstained hTERT-MSCs in time (cultured in 4:1 ratio). Data is representative 
of three independent experiments. (E-H) After 6 hours of co-culture, dye transfer from DiI –stained 
NALM6 cells towards unstained hTERT-MSCs was decreased using three independent TNT inhibiting 
conditions: actin inhibition (E: cytochalasin D, F: latrunculin B), physical disruption by gentle shaking 
(G), or culture in a 3.0 µm transwell system (H). TNT inhibition by gentle shaking, or culture in a 3.0 
µm transwell system was continuous, while the inhibition of TNT signaling with actin inhibitors 
(observed after 6 hours of co-culture) was reversed after 24 hours, due to the short half-life of these 
inhibitors. Data is representative of three independent experiments.
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Supplemental Figure 4. TNT networks between primary cells
Supplemental Figure 4. TNT networks between primary cells. (A-B) Culture of BCP-ALL patient 
cells showed interleukemic TNT formation (arrowhead) after 3 hours. (C-F) Culture of BCP-ALL 
patient MSCs (c: MSC#1, d-f: MSC#2) showed the formation of intermesenchymal TNT networks 
(arrowheads) which have transferred dye (arrow) after 3 hours. (G-J) TNT signaling between primary 
BCP-ALL cells (DiI; yellow) and primary MSCs (DiO; green) after co-culture for 3 hours showed 
bidirectional exchange of lipophilic dye (arrows) via TNTs (white arrowheads). Images are 3D image 
stacks. Data is representative of at least 3 experiments. Scale bars represent 10 µm.
Supplemental Figure 5. Dynamics of TNT formation between primary cells
126
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B C D
1hr23m 1hr26m 2hr32m
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7hr19m 14hr18m  4hr11m
Supplemental Figure 5. Dynamics of TNT formation between primary cells. (A) Time-lapse 
confocal images (3D image stacks) showing TNT formation (white arrowhead) between primary 
BCP-ALL cells (ALL#10; DiI, yellow) and  primary MSCs (pMSC#1; DiO, green) at multiple time 
points. White arrow indicates transfer of dye to recipient cell. Time indicated in the right lower 
corner is the duration from start of the experiment. Orange Hot look-up table (LUT) was used to 
visualize DiI. Scale bars represent 10 µm. (B-D) Single frames of time-lapse confocal microscopy 
experiments (3D image stacks) showing TNT formation and signaling from primary BCP-ALL cells 
(ALL#10; DiI, yellow) and primary MSCs (pMSC#1; DiO, green).
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Supplemental Figure 6. Surface marker expression of primary human MSCs 
A
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D
Supplemental Figure 6. Surface marker expression of primary human MSCs. All primary 
human MSCs were characterized using positive (CD44/ CD90/ CD105/ CD54/ CD73/ CD146/ 
CD166/ STRO-1) and negative surface markers (CD19/ CD45/ CD34). (A-D) Representative graphs 
showing the expression of surface markers on 4 primary MSCs. Blue graphs represent surface 
marker expression. Gray graphs represent expression of isotype controls. 
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ALL#3 TA 97% 3% - - -
ALL#4 TA 98% 1% - - 1%
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Supplemental Figure 7. Characterization of primary leukemic blasts 
Supplemental Figure 7. Characterization of primary leukemic blasts. (A) The percentage 
of processed leukemic cells was determined using May-Grünwald-Giemsa staining of cytospin 
preparations. Images show representative cytospin preparation of leukemic blasts of patient ALL#3. 
Black arrowheads indicate lymphocytes. All other cells are scored as leukemic blasts. (B) Table 
containing blast percentages of primary BCP-ALL samples obtained by scoring at least 200 cells per 
sample. (C) CD19-expression of leukemic blasts was determined for all samples with flow cytometry 
or fluorescence microscopy. Images are representative and show CD19 surface marker expression of 
leukemic blasts of patient ALL#3. Dot plots show CD19 surface marker expression of leukemic blasts 
of patient ALL#3 using flow cytometry.
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Supplemental Figure 8. TNT signaling to healthy and leukemic MSCs is similarly efficient 
Supplemental Figure 8. TNT signaling to healthy and leukemic MSCs is similarly efficient. 
Quantification of dye transfer indicating similarly efficient transfer from DiI-stained REH cells towards 
unstained primary healthy and primary leukemic MSCs (cultured in 4:1 ratio) in time. (A) Dye 
transfer from DiI –stained NALM6 cells towards unstained primary MSCs of a healthy donor. Three 
independent TNT inhibiting conditions (actin inhibition (cytochalasin D; 1µM, latrunculin B; 500 
nM), physical disruption by gentle shaking, or culture in a 3.0 µm transwell system) decreased dye 
transfer from leukemic cells towards primary MSCs. (B) Same as (A) for transfer towards unstained 
primary MSCs of a BCP-ALL patient (B-Other). (C) Same as (A) for transfer towards unstained primary 
MSCs of a BCP-ALL patient (TEL-AML1).
Supplemental Figure 9. Secretion of cytokines induced by primary BCP-ALL cells. (A) MCP-1 
(CCL2) supernatant levels in co-culture of primary leukemic patient ALL#7 cells with primary MSC#1 
(left panel), MSC#2 (middle panel), or MSC#3 (right panel). TNT signaling was inhibited by gentle 
shaking or culture in a transwell system. *p<0.05, **p<0.01 (one-tailed t-test, unpaired). (B) Same 
as (A) for GRO levels. (C) MCP-1 (CCL2) supernatant levels in co-culture of primary leukemic patient 
ALL#9 cells with primary MSC#4 (left panel), or MSC#5 (right panel). (D) Same as (C) for GRO levels. 
(E) IL8 supernatant levels in co-culture of BCP-ALL cells (NALM6) with primary MSC#1 (left panel) or 
MSC#2 (right panel). TNT signaling was inhibited by gentle shaking or culture in a transwell system. 
(F) VEGF supernatant levels in co-culture of BCP-ALL cells (NALM6) with primary MSC#1 (left panel) 
or MSC#2 (right panel). (G) IL8 measurements as seen in (F) relative to the ‘Normal’ condition 
(one-tailed t-test, paired). (H) VEGF measurements as seen in (C) relative to the ‘Normal’ condition 
(one-tailed t-test, paired). Data are means ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001  (one-tailed 
t-test, unpaired). nd = not detectable (below detection level).
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Supplemental Figure 10. TNTs contribute to drug resistance
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Supplemental Figure 10. TNTs contribute to drug resistance. These data represent the same 
experiment as shown in Figure 7B. (A) BCP-ALL cell line NALM6 was cultured with (white bars) or 
without (black bars) MSCs (of three different sources) and cultures were exposed to prednisolone. 
Bars represent the cell count relative to an untreated control. (B) The relative survival benefit for 
NALM6 cells in co-culture with MSCs. Inhibition of TNT signaling (by gentle shaking or culture in 
a 3.0 µm transwell system) re-sensitized to prednisolone (n = 3; one-tailed t-test, unpaired). Data 
are means ± SD. ** p ≤ 0.01 (one-tailed t-test, unpaired).
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Supplemental Figure 11. Model of the TNT-driven l ukemic niche
Supplemental Figure 11. Model of the TNT-driven leukemic niche. Model depicting the role of TNT 
signaling in  leukemic niche formation. Leukemic cells use TNTs to modulate their microenvironment 
by directing non-malignant stromal cells to produce pro-survival cytokines and chemokines. This 
leukemic niche promotes cell survival and drug resistance and can be disrupted by inhibiting 
TNT signaling.
SUPPLEMENTAL VIDEOS
Supplemental Video 1. TNT formation between BCP-ALL cells and MSCs.
TNTs are thin membrane tethers containing F-Actin that do not contact the substratum. 
These videos show that membrane tethers between BCP-ALL cells and MSCs do not 
touch the substratum. (A) Video showing all z-stacks of images shown in Figure 1A-D. 
Video starts at the highest Z-stack and moves towards the fibronectin-coated glass slide. 
(B) Video showing 3D projections of all z-stacks of images in Figure 1A-D. 
Supplemental Video 2. TNT connecting a BCP-ALL cell and a MSC
Video showing a thin membrane tether between a BCP-ALL cell (NALM6; DiI; in red) and 
a MSC (hTERT-MSC; in green) that does not touch the substratum. Dye transfer from 
the BCP-ALL cell to the MSC is illustrated by the presence of red dye in the MSC.
Supplemental Video 3. Time lapse analysis of TNT formation between 
BCP-ALL cells and MSCs
Time-lapse confocal imaging showing TNT formation from NALM6 cells (DiI; yellow) 
towards primary MSCs (DiO; green) in time (red arrows). NALM6 cells were labeled with 
the fluorescent lipophilic dye DiI, and primary MSCs were labeled with the fluorescent 
lipophilic dye DiO. Frames were collected every 3 minutes and 19 seconds and the video 
runs at 3 frames/second, except between 0:09 and 0:15 seconds, where the playback 
speed is increased 1.5 times. All frames are 3D image stacks as described in Figure 3 and 
Supplemental Methods. 3D projections of start and end of experiment are included to 
show the amount of dye transfer and are confocal signals of 561-nm laser overlaid to 
bright field images. 
Supplemental Video 4. Time lapse analysis of TNT formation between 
BCP-ALL cells and MSCs
(A) Time-lapse confocal imaging showing TNT formation from NALM6 cells (DiI; yellow) 
towards primary MSCs (DiO; green) in time (red arrows). Blue arrow indicates a TNT 
formed by MSCs. NALM6 cells were labeled with the fluorescent lipophilic dye DiI, and 
primary MSCs were labeled with the fluorescent lipophilic dye DiO. Frames were collected 
every 3 minutes and 19 seconds and the video runs at 3 frames/second. (B) 3D projections 
of start (0 hr) and end (10 hr) of experiment to illustrate the amount of dye transfer. 
Confocal signals of 561-nm laser are overlaid to bright field images. 
Supplemental videos available online: www.bloodjournal.org.
Chapter 3DISRUPTING TUNNELING NANOTUBE 
SIGNALING IN THE LEUKEMIC NICHE 
USING ACTIN INHIBITORS
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ABSTRACT
Acute lymphoblastic leukemia (ALL) cells use tunneling nanotubes (TNT) to communicate 
with mesenchymal stromal cells (MSCs) and thereby induce cellular drug resistance and 
the secretion of pro-survival cytokines. However, it is currently unclear how to inhibit 
these cytoskeletal structures in the leukemic niche. Here we investigated 6 tubulin and 11 
actin inhibitors for their potency to disrupt signaling in ALL-MSC co-cultures using flow 
cytometric analysis. Our data show that microtubule inhibitors were cytotoxic to both 
ALL cells and MSCs but paradoxically increased TNT signaling up to 2.7-fold (p < 0.05). 
In contrast, inhibiting actin polymerization (swinholide A, cytochalasin D, mycalolide B, or 
latrunculin B), inhibiting actin disassembly (cucurbitacin E or jasplakinolide), or inhibiting 
actin nucleation by targeting formins or the Arp2/3 complex (SMIFH2, CK548), strongly 
reduced TNT signaling up to 20-fold (p < 0.001). Interestingly, combining inhibitors of actin 
stabilization and polymerization as well as simultaneous targeting of actin stabilization 
and nucleation significantly reduced  TNT signaling compared to single agents. Similar to 
Vinca alkaloids, actin inhibitors reduced the viability of primary ALL cells. These findings 
provide novel insights into the biology of TNTs in the leukemic niche and indicate that 
cytoskeleton-interfering drugs other than Vinca alkaloids may be of additional benefit in 
the treatment of ALL.
KEY POINTS
Tunneling nanotube signaling between leukemic cells and mesenchymal stromal cells is 
inhibited by disrupting actin not tubulin.
Simultaneously targeting actin disassembly and actin nucleation or polymerization 
reduces  TNT signaling in a synergistic-like manner. 
INTRODUCTION
The structure of eukaryotic cells is regulated by a dynamic cytoskeletal matrix, mainly 
composed of three polymers: microtubules, microfilaments (or actin filaments) and 
intermediate filaments. These cytoskeletal proteins spatially organize the contents of 
the cell, physically and biochemically connect the cell to its microenvironment and facilitate 
cell shape and movement1. Each type of filament has unique characteristics and regulates 
specific biological processes. For example, actin filaments drive cellular protrusions which 
are involved in chemotaxis and cell-cell communication1. Recently, new cytoskeletal 
structures called tunneling nanotubes (TNTs) have been discovered. TNTs reach lengths of 
multiple cell diameters, protrude from the cell membrane, and connect the cytoskeleton 
of two cells2. These structures are driven by the polymerization of monomeric, or globular, 
actin into filamentous actin (F-actin)2,3. TNTs facilitate intercellular transport of pathogens, 
organelles, proteins and calcium fluxes2,4-7. They have been identified in multiple cell types, 
including cancer cells2,3,6,8-12. We recently showed that TNTs support leukemic cell survival 
and drug resistance in acute lymphoblastic leukemia (ALL)13. In addition, TNT signaling 
between ALL cells and mesenchymal stromal cells (MSCs) induced the secretion of 
pro-survival cytokines in the tumor microenvironment13. TNT inhibition reversed this 
cytokine signature and subsequently sensitized leukemic cells toward chemotherapeutic 
drugs13. These findings suggest that TNT inhibition may offer a promising new therapeutic 
option. Unfortunately, agents that specifically inhibit TNTs have not yet been identified. 
Since TNT signaling depends on actin and/or tubulin2,13-15, we investigated 6 tubulin and 
11 actin inhibitors for their potency to disrupt TNT signaling between ALL cells and MSCs. 
In addition, we studied how these compounds affect the viability of primary ALL cells, 
CD34+ hematopoietic progenitor cells (HPCs), hematopoietic mononuclear cells (MNCs), 
and MSCs.
METHODS
BCP-ALL cells
BCP-ALL cell line NALM6 (B-Other), obtained from DSMZ (Braunschweig, Germany), was 
used at low cell passages and routinely verified by DNA fingerprinting.  Patient cells were 
obtained from bone marrow aspirates from children with newly diagnosed BCP-ALL prior 
to treatment. Mononuclear leukemic cells were collected and processed as previously 
described16. All samples used in this study contained ≥ 95% leukemic blasts. 
Isolation and characterization of healthy cells
Mesenchymal stromal cells (MSCs) were isolated from bone-marrow aspirates and 
characterized as previously described13,17. In short, MSCs were confirmed to have 
multilineage potential for adipocyte, osteocyte and chondrocyte differentiation and 
characterized using positive (CD44/ CD90/CD105/CD54/CD73/CD146/CD166/STRO-1) 
and negative surface markers (CD19/CD45/CD34).
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Human mononuclear cells (MNCs) were obtained from umbilical cord blood (UBC) 
based on a density gradient using Lymphoprep (Stemcell Technologies, Köln, Germany). 
CD34+ hematopoietic progenitor cells (HPCs) were obtained from UBC using the Direct 
CD34 Progenitor Cell Isolation kit, human (Miltenyi Biotec, Gladback, Germany). CD34+ 
HPCs were positively selected by magnetic microbeads using the MACS LS column 
(Miltenyi Biotec) in combination with a MACS separator (Miltenyi Biotec). Isolated cells 
were confirmed to be CD34+ by flow cytometry using the CD34-PE fluorescent antibody 
(BD Pharmingen, San Diego, USA).
Confocal laser scanning microscopy 
NALM6 cells were stained with 1,1’-dioctadecyl-3,3,3’3’-tetramethylindocarbocyanine 
perchlorate (DiI; yellow) and MSCs were stained with 3,3’-dioctadecyloxacarbocyanine 
(DiO; green; both from Life Technologies, Breda, The Netherlands) according to 
the manufacturer’s protocol. NALM6 cells and MSCs were co-cultured in a 4:1 ratio on 
a glass slide coated with 10 µg/mL fibronectin (Sigma-Aldrich, Saint Louis, USA) at 37 
°C and 5% CO2 for 3 hours and fixated as previously described
13,18. Confocal images 
were acquired as previously described using a Leica SP513. In short, we used sequential 
scanning of different channels at a resolution of 1024 x 1024 pixels in the x x y plane and 
0.15 µm steps in z-direction. DiO and DiI were excited with a 488-nm Argon laser and 
a 561-nm Diode-Pumped Solid-State laser, respectively. Image processing was done with 
Fiji software19.
Dye transfer experiments
CD19-positive BCP-ALL cells were stained with DiI and co-cultured with unstained 
CD19-negative MSCs for 3 or 24 hours in a 4:1 ratio. ALL-MSC co-cultures were either 
untreated (control) or treated with tubulin or actin inhibitors (Table 1). At the end of each 
experiment, cells were harvested and stained with brilliant violet 421-labelled anti-human 
CD19 antibody (Biolegend, San Diego, USA) to separate cell types, and stained with Sytox 
Red (Sigma-Aldrich) to distinguish live and apoptotic events (See supplemental Figure 1 
for gating strategy). The median intensity of DiI-label was determined for viable MSCs 
using the PE-channel and taken as a measure of dye transfer. Target populations were 
analyzed before and after co-culture with flow cytometry (BD Bioscience, San Jose, USA).
Cell viability assay
The effect of tubulin and actin inhibitors on multiple cell types was assessed using 
a colorimetric assay. All cells were cultured in round-bottom 96-well plates and 
incubated with inhibitors for 48 hours, except MSCs which were cultured on flat-
bottom 96-well plates. At the end of experiment, MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was added to each well 
(20 µL / well) and conversion of MTS was detected by a spectrophotometer at 490 nm. 
The amount of MTS conversion in the presence of inhibitors was normalized relative to an 
untreated control and used as a measure of cell viability. For primary BCP-ALL cells, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used.
Statistical analysis
Student’s t-test was used as a statistical test and a Student’s paired t-test was used 
when applicable (indicated in figure legends). Error bars show as standard error of 
the mean (SEM).
Table 1. Overview of tubulin and actin inhibitors
Name Target Mechanism of action
Taxola tubulin Enhances tubulin polymerization and stabilization20
Colchicinea tubulin Inhibits microtubule polymerization21
Nocodazolea tubulin Inhibits microtubule polymerization22
Vinblastinea tubulin Inhibits microtubule polymerization21
Colcemida tubulin Inhibits microtubule polymerization23
Vincristinea tubulin Inhibits microtubule polymerization23
Swinholide Aa,b actin Stabilizes actin dimers and severs actin24
Mycalolide Bc,d actin Stabilizes actin dimers and severs actin25,26
Latrunculin Ba actin Alters the actin-monomer subunit interface27
Cytochalasin Da actin Blocks fast growing end of actin filaments28
Cucurbitacin Ea actin Inhibits depolymerization by binding to F-actin29
Jasplakinolidec actin Decreases sequestering of actin30,31
ML141a actin Cdc42 inhibitor32
SMIFH2a actin Formin inhibitor
CK548a,d actin Arp2/3 inhibitor
Wiskostatina actin N-wasp inhibitor33
Blebbistatind actin Myosin-II inhibitor34
Company information: a = Sigma-Aldrich (Saint Louis USA), b = AG Scientific (San Diego, USA), 
c = Abcam (Cambridge, UK), d = Enzo Life Sciences (New York, USA).
RESULTS
TNT signaling is accurately quantified by lipophilic dye transfer
Confocal microscopy was used to visualize the presence of TNTs between B-cell precursor 
ALL (BCP-ALL) cells and MSCs as earlier described13. TNTs connecting BCP-ALL cells 
(NALM6, stained with DiI-yellow) and primary MSCs (stained with DiO-green) were 
visible after 3 hours of co-culture and showed transport of lipophilic dye toward MSCs 
(Figure 1A, supplemental Figure 2). 3D reconstruction of confocal images confirmed that 
these TNTs did not connect with the substratum (i.e. the fibronectin-coated glass slide; see 
supplemental Video 1A-D and supplemental Video 2A-D). Confocal microscopy visualizes 
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TNT structures, but is less suited to measure the signaling through TNTs. Measuring 
lipophilic dye transfer from ALL cells toward MSCs using flow cytometry is an accurate 
way to quantify TNT signaling2,3,13. Within 3 hours of co-culture, DiI-labeled NALM6 cells 
transferred dye to more than 50% of MSCs and this increased to > 95% after 24 hours 
(Figure 1B).
Figure 1. TNT signaling is accurately quantified by measuring lipophilic dye transfer
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Figure 1. TNT signaling is accurately quantified by measuring lipophilic dye transfer. (A) 
Representative confocal images (Z-stack) showing TNT networks (white arrowheads) between 
BCP-ALL cell line NALM6 (DiI, yellow) and primary MSCs (DiO, green) after co-culture for 3 hours 
(n = 4). Lipophilic dye transfer toward MCSs via TNTs was observed (yellow dye in green MSCs). 
(B) Graph showing quantification of dye transfer from DiI-stained NALM6 cells toward unstained 
MSCs after 3 (light-grey histogram) and 24 hours (grey histogram) of co-culture (n = 20). See also 
supplemental Figures 1 and 2 and supplemental Video 1A-D and 2A-D.
Tubulin inhibitors do not inhibit TNT signaling between BCP-ALL cells 
and MSCs
Next, we assessed the effect of tubulin inhibitors on lipophilic dye transfer by flow 
cytometry. We used a broad range of concentrations based on those reported to be 
effective in literature (for references see Table 1). Tubulin disruption for 48 hours by six 
different tubulin inhibitors caused a marked decrease in cell viability of leukemic cells and 
MSCs (supplemental Figure 3). However, this was not preceded by reduced lipophilic dye 
transfer. Instead, dye transfer was increased by all tubulin inhibitors (Figure 2, ≤ 2.7-fold 
increase, p < 0.05). These data show that TNT signaling between BCP-ALL cells and MSCs 
cannot be inhibited by interference with microtubules. In addition, these data suggest 
that TNT signaling is enhanced during treatment with tubulin inhibitors.
Figure 2. Tubulin inhibitors do not inhibit TNT signaling between BCP-ALL cells and MSCs
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Figure 2. Tubulin inhibitors do not inhibit TNT signaling between BCP-ALL cells and MSCs. 
(A) Graph showing quantification of dye transfer from DiI-stained NALM6 cells toward unstained 
MSCs with (red histogram) or without (grey histogram) treatment with 1 µM taxol for 24 hours (n = 
2). (B) Graph showing quantification of dye transfer from DiI-stained NALM6 cells toward unstained 
MSCs. Co-cultures were treated with or without taxol using multiple concentrations (two-tailed 
t-test, unpaired) (n = 2). (C) Same as (A) for 200 µM colchicine (n = 3). (D) Same as (B) for colchicine 
(n = 3). (E) Same as (A) for 1 µM colcemid (n = 2). (F) Same as (B) for colcemid (n = 2). (G) Same as 
(A) for 80 µM nocodazole (n = 2). (H) Same as (B) for nocodazole (n = 2). (I) Same as (A) for 10 µM 
vinblastine (n = 2). (J) Same as (B) for vinblastine (n = 2). (K) Same as (A) for 100 ng/mL vincristine 
(n = 2). (L) Same as (B) for vincristine (n = 2). Data are means ± SEM; ** p ≤ 0.01, *** p ≤ 0.001. 
See also supplemental Figure 1 and 3.
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TNT signaling between BCP-ALL cells and MSCs is dependent on actin 
polymerization, disassembly and nucleation
Next, we used the ALL-MSC co-culture model to investigate the ability of 11 actin 
disrupting molecules to inhibit TNT signaling. Actin inhibitors can be subdivided into 
four different classes, namely those affecting the polymerization, the disassembly, 
the nucleation or the rearrangement of actin molecules (Figure 3). The concentration 
range of the inhibitors was based upon those reported to be effective in literature (for 
references see Table 1). Like tubulin inhibitors, all actin inhibitors caused a decrease in cell 
viability of leukemic cells and MSCs after 48 hours of exposure (supplemental Figure 4). 
All four actin polymerization inhibitors significantly reduced dye transfer from 
BCP-ALL cells toward MSCs within 24 hours of exposure (Figure 4A-B, ≤ 92% reduction, 
p < 0.001). This is in line with literature showing that inhibition of actin polymerization 
inhibits TNT formation2,35-37. Next we assessed the effect of the actin disassembly 
inhibitors cucurbitacin E and jasplakinolide. Interestingly, both molecules strongly 
reduced lipophilic dye transfer toward MSCs (Figure 4C-D; ≤ 95% reduction at 250 nM 
cucurbitacin E or jasplakinolide, p < 0.001). Jasplakinolide has been reported to affect 
the length of TNTs in microvascular endothelial cells and to reduce the formation of 
TNTs between cells38,39. Our data show that stabilization of the actin cytoskeleton also 
reduces signaling via TNTs. Actin nucleation factors mimic actin monomers and hereby 
create a stable starting point for actin polymerization. Inhibiting actin nucleation by either 
SMIFH2 (formin inhibitor)40 or CK548 (Arp2/3 inhibitor)41 strongly reduced dye transfer 
from BCP-ALL cells toward MSCs, although only at high concentrations (96% reduction 
at 37.5 µM SMIFH2 or 200 µM CK548, p < 0.001; Figure 4E-F). To our knowledge, this is 
the first report showing that actin nucleation is important for TNT signaling. Finally, we 
explored the effects of small-molecule inhibitors interfering with proteins that rearrange 
the actin cytoskeleton. ML141 (Cdc42 inhibitor)32 was unable to reduce lipophilic dye 
transfer, wiskostatin (N-wasp inhibitor)33 slightly affected dye transfer (32% reduction at 
12.5 µM, p < 0.05) and (±)-blebbistatin (Myosin II inhibitor)34 stimulated dye transfer at 
higher concentrations (2.1-fold at 50 µM, p < 0.001; Figure 4G-H). These findings show 
that actin nucleation, polymerization, and disassembly are important for TNT signaling 
between ALL cells and MSCs.
Inhibitors identified in NALM6 cells also inhibit TNT signaling in primary 
BCP-ALL cells
Next we tested the most promising compounds in our cell line studies using co-cultures 
of patient-derived BCP-ALL cells and MSCs. We selected these compounds based on TNT 
inhibiting capacity and cytotoxicity. Cytochalasin  D, cucurbitacin  E, jasplakinolide and 
CK548 significantly reduced the dye transfer from primary BCP-ALL cells toward MSCs 
in 24 hours (Figure 5A-B, p < 0.001). Interestingly, both jasplakinolide and CK548 were 
less potent in inhibiting dye transfer in primary BCP-ALL cells compared to NALM6 cells 
Actin filament
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ARP2 Formins
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Actin
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Actin
disassembly
Swinholide A
Mycalolide B
Latrunculin B
Cytochalasin D
Cucurbitacin E
Jasplakinolide
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Actin rearrangement
Actin Cytoskeleton
ML141
SMIFH2
Blebbistatin
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Figure 3. Schematic overview of compounds disrupting actin biosynthesis and breakdown
N-WASP
Wiskostatin
Actin
nucleation
Figure 3. Schematic overview of compounds disrupting actin biosynthesis and breakdown. 
Schematic overview showing the regulation of the actin cytoskeleton by actin nucleation, 
polymerization, rearrangement, and disassembly. White boxes show actin inhibitory molecules. See 
also Table 1.
(61% versus 95% reduction at 500 nM jasplakinolide; 27% versus 96% reduction at 
200 µM CK548; Figure 4 and 5). These data show that inhibitors of actin nucleation, 
polymerization, and disassembly also effectively reduce TNT signaling between primary 
BCP-ALL cells and primary MSCs.
Inhibiting the actin cytoskeleton reduces cell viability in healthy and 
leukemic cells
We tested the cytotoxic effect of cytochalasin  D, cucurbitacin  E, jasplakinolide and 
CK548 exposure for 48 hours in primary BCP-ALL cells (n = 6), primary MSCs (n = 3), 
umbilical cord-blood derived CD34+ HPCs (n = 2) and umbilical cord-blood derived MNCs 
(n = 6). Red areas indicate the drug concentrations resulting in profound inhibition of dye 
transfer via TNTs after 24 hours of exposure (Figure 6). Exposure to cytochalasin D had no 
effect on the viability of MNCs and CD34+  HPCs, and only a limited effect on BCP-ALL 
cells (21% reduction in cell viability at 1000 nM), compared to MSCs (65% reduction 
in cell viability at 1000 nM; Figure 6A). Cucurbitacin E had a limited effect on MNCs 
(28% reduction at 1000 nM; Figure 6B), but strong effects on the viability of primary 
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Figure 4. TNT signaling between BCP-ALL cells and MSCs is dependent on actin polymerization, 
actin disassembly and actin nucleation. (A) Graphs showing quantification of dye transfer from 
DiI-stained NALM6 cells towards unstained MSCs with (red histograms) or without (grey histograms) 
treatment by inhibitors depicted in (B). (B) Graph showing quantification of dye transfer after 24 
hours from DiI-stained NALM6 cells toward unstained MSCs. Co-cultures were treated with or 
without the actin polymerization. inhibitors swinholide A, cytochalasin D, mycalolide B or latrunculin 
B. Data is representative of at least three independent experiments (two-tailed t-test, unpaired). (C) 
Same as (A) for actin disassembly inhibitors cucurbitacin E and jasplakinolide. (D) Same as (B) for 
actin disassembly inhibitors cucurbitacin E and jasplakinolide. (E) Same as (A) for actin nucleation 
inhibitors SMIFH2 and CK548. (F) Same as (B) for actin rearrangement inhibitors SMIFH2 and 
CK548. (G) Same as (A) for actin rearrangement inhibitors ML141, wiskostatin and (±)-blebbistatin. 
(H) Same as (B) for actin rearrangement inhibitors ML141, wiskostatin and (±)-blebbistatin. Data 
are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.  See also supplemental Figures 1 and 4.
Figure 4. Tunneling nanotube signaling between BCP-ALL cells and MSCs
is dependent on the actin polymerization, actin disassembly and actin nucleation
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Figure 5. Inhibitors identified in NALM6 cells also inhibit TNT signaling in primary BCP-ALL 
cells. (A) Graphs showing quantification of dye transfer from primary BCP-ALL cells from 4 different 
patients toward unstained MSCs with (red histograms) or without (grey histograms) treatment by 
inhibitors cytochalasin D, cucurbitacin E, jasplakinolide or CK548. (B) Quantification of dye transfer 
experiment exemplified in (A) performed with 2 different concentrations for each inhibitor (one-
tailed t-test, paired; n = 4). Data are means ± SEM; *** p ≤ 0.001. See also supplemental Figure 1 
and Figure 6.
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BCP-ALL cells, MSCs and CD34+ HPCs (81% reduction for BCP-ALL, 78% reduction for 
MSCs and 72% reduction for CD34+ HPCs at 1000 nM; Figure 6B). Jasplakinolide strongly 
affected MSC viability (87% reduction at 1000 nM), whereas the toxic effect was less 
pronounced for primary BCP-ALL cells, CD34+ HPCs (59% reduction at 1000 nM), and 
MNCs (19% reduction at 1000 nM; Figure 6C). The actin nucleation inhibitor CK548 was 
detrimental to all cell types at high concentrations (> 100 µM CK548, ≤ 88% reduction 
in cell viability; Figure 6D). These data show that actin inhibitors are toxic to leukemic 
and healthy hematopoietic and stromal cells, which is in line with previous findings for 
tubulin inhibitors21,42,43.
Actin nucleation and actin polymerization regulate TNT signaling 
together with actin disassembly
Next, we determined if actin nucleation, polymerization, and/or disassembly cooperate or 
independently regulate TNT signaling. For each inhibitor a concentration was used that had 
limited effect in inhibiting TNT signaling as a single agent in ALL-MSC co-cultures (50 nM 
cytochalasin D ,120 nM jasplakinolide and 25 µM CK548; Figure 7A). Targeting both actin 
Figure 6. Inhibiting the actin cytoskeleton reduces cell viability in healthy and leukemic cells
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Figure 6. Inhibiting the actin cytoskeleton reduces cell viability in healthy and leukemic 
cells. (A) Graph showing the effect of cytochalasin D on cell viability of BCP-ALL cells (n = 6), MNCs 
(n = 6), CD34+ HPCs (n = 2) and MSCs (n = 3) derived from patients as measured by a MTS assay 
(primary BCP-ALL cells were measured using a MTT assay). The red area represents concentrations 
at which cytochalasin D inhibits dye transfer from BCP-ALL cells toward MSCs. (B) Same as (A) for 
cucurbitacin E. (C) Same as (A) for jasplakinolide. (D) Same as (A) for CK548. Data are means ± SEM. 
See also supplemental Figure 4.
nucleation and polymerization by co-treatment with CK548 and cytochalasin D did not 
reduce dye transfer (Figure 7B). Interestingly, simultaneous inhibition of actin disassembly 
by jasplakinolide in combination with inhibition of actin polymerization (cytochalasin D) 
or nucleation (CK548) was more effective than each of the single agents (Figure 7B-D, 
p < 0.05). These data suggest synergism between actin disassembly inhibitors and 
inhibitors of actin polymerization and actin nucleation.Figure 7. Simultaneous inhibition of actin disassembly and actin polymerization
or nucleation synergistically inhibits TNTs
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Figure 7. Simultaneous inhibition of actin disassembly and actin polymerization or 
nucleation synergistically inhibits TNTs. (A) Graphs showing quantification of dye transfer from 
DiI-stained NALM6 cells towards unstained MSCs with (red histograms) or without (grey histograms) 
single treatment of actin inhibitors CK548 (25 µM), cytochalasin D (50 nM) or jasplakinolide (120 
nM). Blue histogram shows DiI-positivity of MSCs at the start of experiment (n = 3). (B) Graphs 
showing quantification of dye transfer from DiI-stained NALM6 cells towards unstained MSCs with 
(green histograms) or without (grey histograms) combination treatment of actin inhibitors CK548, 
cytochalasin D or jasplakinolide (n = 3). (C) Quantification of dye transfer experiments exemplified 
in (A) and (B) performed with CK548 and jasplakinolide (n = 3; one-tailed t-test paired). (D) Same as 
(C) for cytochalasin D and jasplakinolide (n = 3; one-tailed t-test paired). Data are means ± SEM; * 
p ≤ 0.05, ** p ≤ 0.01. See also supplemental Figure 1.
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DISCUSSION
TNTs regulate the resistance of tumor cells to chemotherapeutic agents in multiple 
cancers, showing the strong need for TNT inhibitors11,13,14. Disruption of TNTs through 
physical separation of cells or mechanical disruption has been shown to sensitize leukemic 
cells to prednisolone and prevent the secretion of pro-survival factors13. Unfortunately, 
these techniques cannot be used in in vivo models and cancer patients. There is a large 
variety in the composition, length, width, and lifespan of TNTs across cell types2,3,13,38,44. 
However, the main components of TNTs are reported to be actin and or tubulin. We 
therefore assessed the effect of tubulin and actin disrupting agents on the exchange 
of a lipophilic dye that it is transported by TNTs from BCP-ALL cells toward MSCs13. In 
previous experiments, we showed that the contribution of other cell-cell communication 
mechanisms to dye transfer is negligible13.
Importantly, our study revealed that interference with microtubules induces dye 
transfer via TNTs (Figure 2). This increase is not explained by the release of dye by apoptotic 
cells, since similar toxicity induced by actin inhibitors did not promote dye transfer 
(Figure 4-6, supplemental Figures 3 and 4). The induction of TNT signaling by tubulin 
inhibitors supports earlier observations that TNT formation is increased in response to 
cellular stress12,45. Importantly, tubulin inhibitors are used in the treatment of ALL patients 
worldwide. The finding that these drugs induce TNT signaling possibly uncovers a rescue 
mechanism triggered in leukemic cells in response to treatment.
In contrast to tubulin, all TNTs have been reported to contain actin. Therefore, we 
assessed actin perturbing compounds with different working mechanisms for their ability 
to inhibit TNT signaling between BCP-ALL cells and MSCs (Table 1). Inhibitors of actin 
nucleation, actin polymerization and actin disassembly were all effective in disrupting 
TNT signaling. To increase our insight in how these mechanisms are intertwined, we 
investigated the effect of combining actin inhibitors of different classes. Simultaneous 
inhibition of actin polymerization (cytochalasin D) and actin nucleation (CK548) did not 
reveal a synergistic effect (Figure 7). This can be explained by the fact that actin nucleation 
is directly responsible for the initiation of actin polymerization and hence both inhibitors 
affect the same process. In contrast, simultaneous targeting of actin disassembly and 
actin nucleation or actin polymerization did affect TNT signaling more than would be 
expected if the effect was additive (Figure 7). These results show that TNT signaling is 
driven by the interplay of fundamental actin regulating processes in leukemic cells. 
The actin cytoskeleton is often transformed in malignant cells46-48, for example by 
deregulation of formins49. Consequently, actin inhibitors are being investigated as novel 
anti-cancer drugs50,51. Actin is present in all eukaryotic cells and hence might lead to 
toxicity of these compounds52-54. We observed that MNCs were relatively more resistant 
to actin inhibition than BCP-ALL cells, while primary MSCs and CD34+ HPCs were also 
affected. Therefore, actin inhibitors should be used with caution. Likewise, tubulin 
inhibitors induce significant side-effects, like peripheral neuropathy42, cardiovascular 
and thromboembolic events43. Nevertheless, it has been argued that tubulin inhibitors 
represent the most successful class of anti-cancer agents thus far, and they will likely 
remain important even as more selective drugs are developed21,28,55. Therefore, actin 
inhibitors might become an important novel class of anti-leukemic agents which induce 
cytotoxicity and disrupt the intercellular communication between leukemic cells and 
the bone marrow microenvironment.
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Supplemental Figure 1. Gating strategy to measure dye transfer from BCP-ALL toward MSCs
MSCs
BCP-ALL
Supplemental Figure 1. Gating strategy to measure dye transfer from BCP-ALL toward MSCs. 
Flow cytometric gating strategy used to study TNT signaling from BCP-ALL cells toward MSCs. Co-
cultures of CD19-positive leukemic cells and CD19 -negative MSCs were stained with Sytox Red and 
Brilliant Violet 421 anti-human CD19 antibody. Sytox Red-positive events (apoptotic events) were 
excluded and CD19 positivity was evaluated to distinguish BCP-ALL cells and MSCs. At the start of 
each experiment, MSCs were confirmed to be negative for DiI and NALM6 cells were confirmed to 
be positive for DiI using the PE-channel. At the end of the experiment, median intensity of viable 
MSCs for the PE-channel was used as a measure of dye transfer. 
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Supplemental Figure 2. Tunneling nanotube formation between BCP-ALL cells and MSCs
Supplemental Figure 2. Tunneling nanotube formation between BCP-ALL cells and MSCs. 
Confocal images (Z-stack) showing TNT networks (white arrowheads) between BCP-ALL cell line 
NALM6 (DiI, yellow) and primary MSCs (DiO, green) after co-culture for 3 hours. Lipophilic dye 
transfer toward MCSs via TNTs was observed (yellow dye in green MSCs). See also supplemental 
Video 1A-D and supplemental Video 2A-D.
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Supplemental Figure 3. Tubulin inhibition decreases cell viability of NALM6 cells and MSCs. 
(A) Graph showing the effect of tubulin inhibitor Taxol on cell viability of NALM6 cells and MSCs. (B) 
Same as (A) for colchicine. (C) Same as (A) for colcemid. (D) Same as (A) for nocodazole. (E) Same 
as (A) for vinblastine. (F) Same as (A) for vincristine.
Supplemental Figure 4. Actin inhibition decreases cell viability of NALM6 cells and MSCs
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Supplemental Figure 4. Actin inhibition decreases cell viability of NALM6 cells and MSCs. 
(A) Graphs showing the effect of actin polymerization inhibitors swinholide A, cytochalasin D, 
mycalolide B or latrunculin B on cell viability of NALM6 cells and MSCs. The red area represents 
concentrations at which TNT signaling is inhibited. (B) Same as (A) for actin disassembly inhibitors 
cucurbitacin E and jasplakinolide. (C) Same as (A) for actin nucleation inhibitors SMIFH2 and CK548. 
(D) Same as (A) for actin rearrangement inhibitors ML141, wiskostatin, and (±)-blebbistatin. 
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ABSTRACT
Acute lymphoblastic leukemia (ALL) cells create a leukemic niche with mesenchymal 
stromal cells (MSCs). Cytoskeletal structures called tunneling nanotubes (TNTs) facilitate 
communication between ALL cells and MSCs by transporting molecules and inducing 
the secretion of pro-survival cytokines. The identity of the molecules driving these 
malignant processes are currently unknown. Here we investigate which structures are 
transported from ALL cells toward MSCs by quantifying the transfer of ectopically 
expressed fluorescent marker proteins using flow cytometry. Our results indicate that 
actin, endoplasmatic reticulum, ICAM1, autophagosomes, mitochondria, and endosomes 
are contact-dependently transferred from leukemic cells toward MSCs. Transfer of 
mitochondria, adhesion molecule ICAM1, and autophagosomes were significantly reduced 
(≤ 9.6-fold) when TNT signaling was inhibited. Autophagosomes and mitochondria are 
known inducers of cytokine signaling and hence their transfer might unveil an important 
mechanism that ALL cells use to affect their microenvironment. Importantly, transfer 
of autophagosomes was 3.0-fold greater than the other molecules tested in ALL-MSC 
co-cultures, and has not been previously associated with TNT signaling. These data provide 
insight into intercellular signaling in the leukemic niche and implicate autophagosomes 
as novel TNT cargo.
Authors declare that there are no competing financial interests in relation to the work 
described.
Acute lymphoblastic leukemia (ALL) cells disrupt the healthy bone marrow 
microenvironment to create a leukemic niche that is crucial for facilitating leukemogenesis 
and protects leukemic cells from chemotherapeutic agents and immune cells1, 2. 
However, the functional mechanisms that regulate this malignant process are largely 
unknown. Recently, we showed that tunneling nanotubes (TNTs) play an important role 
in the communication between leukemic cells and bone-marrow derived mesenchymal 
stromal cells (MSCs)3, 4. TNTs are thin membrane protrusions that are driven by the actin 
cytoskeleton5. We recently showed that ALL cells use TNTs to signal toward MSCs and 
subsequently induce the secretion of pro-survival cytokines, leukemic cell survival and drug 
resistance4. B-cell precursor ALL (BCP-ALL) cells and MSCs exchange lipophilic molecules 
using TNTs4. However, the identity of the transported cargo needs further elucidation. 
In this study, we describe that autophagosomes, mitochondria and the transmembrane 
protein ICAM1 are transferred from B-cell precursor ALL (BCP-ALL) cells toward MSCs in 
a TNT-dependent manner. 
To identify which structures are transferred from leukemic cells to MSCs via TNTs, we 
ectopically (i.e. non-endogenously) expressed fluorescently tagged proteins that mark 
specific cellular structures in BCP-ALL cells (NALM6) using lentiviral vectors (Figure 1A 
and supplemental Figure 1). After lentiviral transduction, we obtained stable BCP-ALL cell 
clones expressing turbo RFP (tRFP)-tagged marker proteins. The tRFP-positive BCP-ALL 
cells were stained with a nucleus specific dye (NucBlue), after which specific subcellular 
localization of fluorescent marker proteins was confirmed by confocal microscopy (Figure 
1B). For example, CALR, which marks the endoplasmatic reticulum (ER), was expressed at 
the nuclear border (Figure 1B second panel from the top). 
Next, we co-cultured tRFP-marker protein expressing BCP-ALL cells with tRFP-negative 
MSCs (Figure 1C) and quantified the transfer of tRFP by flow cytometry (Figure 1D). 
The B-cell marker CD19 was used to distinguish between BCP-ALL cells and MSCs 
(Figure 1D, second panel). Actin, ER, cytoplasm, ICAM1, autophagosomes, mitochondria, 
and early/late/recycle endosomes were transferred from BCP-ALL cells to MSCs, since 
MSCs became increasingly positive for tRFP signal after co-culture with tRFP-tagged 
leukemic clones for 24, 48, and 72 hours (Figure 2A). To exclude that tRFP transfer was 
nonspecific, we plotted the intensity of tRFP in BCP-ALL cells, that differed 6.9-fold 
between the brightest and dimmest clone (cytoplasm versus ER; supplemental Figure 
2), against the intensity of tRFP in MSCs after co-culture for 48 hours (Figure 2B). No 
correlation was found between the amount of transfer and the intensity of the tRFP 
signal in the leukemic clone from which the tRFP-tagged molecule originated (Figure 2B; 
p = 0.48, Pearson correlation test), showing that the observed transfer is not explained 
by nonspecific leakage of tRFP label. This implies that tRFP transfer from BCP-ALL cells 
toward MSCs is representative for transfer of tagged cellular structures. Autophagosomes 
appeared to be the most highly transported structure from BCP-ALL cells to MSCs (3.0-fold 
more than other proteins after 48 hours; Figure 2C). To assess the contribution of TNTs to 
the transfer of cellular structures, we performed ALL-MSC co-cultures in the absence or 
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Figure 1. Identifying TNT cargo using fluorescently tagged proteins
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Figure 1. Identifying TNT cargo using fluorescently tagged proteins. (A) Schematic overview 
of ectopically expressed marker proteins that were used to visualize specific cellular structures in 
BCP-ALL cells (NALM6). (B) Representative confocal images showing the subcellular localization of 
tRFP-positive marker proteins relative to the nucleus in live NALM6 cells. A transmission image is 
provided to show the shape of the leukemic cell (left panel). (C) Experimental setup for visualizing 
protein transfer from BCP-ALL cells toward MSCs. Leukemic clones that express tRFP-positive marker 
proteins were co-cultured with tRFP-negative MSCs and transfer of protein toward was quantified 
by flow cytometry. (D) Gating strategy that was used to quantify transfer of tRFP-positive marker 
protein from leukemic cells toward MSCs by flow cytometry. BCP-ALL cells and MSCs are gated 
based on their forward and sideward scatter (first panel) and separated based on CD19 expression 
(second panel). Finally, the median tRFP signal in MSCs was quantified with the PE-channel and used 
as a measure of tRFP-positive marker protein transfer (last panel). See also supplemental Figure 1.
Figure 2. Autophagosomes, mitochondria, and ICAM1 are transported via tunneling nanotubes
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Figure 2. Autophagosomes, mitochondria and ICAM1 are transferred via tunneling 
nanotubes. (A) BCP-ALL cells expressing tRFP-markers were co-cultured with tRFP-negative MSCs 
for 24 (black bars), 48 (dark-grey bars), and 72 hours (light-grey bars). Median intensity of MSCs for 
tRFP is shown. (B) Graph showing the median tRFP intensity of MSCs (X-axis) compared to BCP-ALL 
tRFP intensity (Y-axis) after co-culture for 48 hours as depicted in Figure 2A. No correlation was 
found indicating that transfer of tRFP was protein specific (n = 3, p = 0.48, Pearson correlation test). 
(C) Graph showing the transfer of tRFP from BCP-ALL cells toward MSCs after 48 hours of co-culture 
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presence of TNT inhibiting conditions for 48 hours. TNTs were inhibited by two established 
approaches in literature: mechanical disruption of TNTs through gentle shaking of cell 
cultures and physical separation of BCP-ALL cells and MSCs using a transwell system 
(3.0 µm pore size)4, 6. While actin inhibitors are often used to inhibit TNTs, their short 
half-time and high cytotoxicity prevented their use in these experiments4. Transfer of 
actin (ACTB), endoplasmatic reticulum (CALR), cytoplasmic content (Empty Vector), and 
endosome markers (RAB family) were inhibited by transwell conditions, but not by gentle 
shaking (Figure 2D). This implicates that transfer of these proteins is driven by cell-cell 
signaling modules other than TNTs. For example by gap junctional protein Cx43, which 
has been shown to be involved in transfer of extracellular vesicles7. Interestingly, transfer 
of transmembrane protein ICAM1, autophagosomes (LC3B), and mitochondria (PDHA1) 
were significantly inhibited by both TNT inhibiting conditions (shaking and transwell; 
p < 0.05, Figure 2D). Transmembrane proteins and mitochondria have previously been 
observed to be transferred via TNTs by other cell types8, 9. Our data show that this is 
also true for TNT signaling between BCP-ALL cells and MSCs. Strikingly, transfer of 
autophagosomes was 3.0-fold higher than ICAM1 and PDHA1 transfer (Figure 2C). To 
our knowledge, this is the first time that autophagosome transfer is observed between 
ALL cells and MSC in a TNT-dependent manner. 
Autophagy is a process that degrades and recycles unwanted or damaged cellular 
components, like proteins and organelles10. This process has been implicated as an 
important regulator of both tumor-initiation and tumor-suppression11. Autophagy is 
driven by double-membraned vesicles known as autophagosomes, which are shaped 
through the actin cytoskeleton12. TNT formation is also dependent on actin4, 5 and this co-
dependence might be important for autophagosome transport through the TNT machinery. 
Interestingly, autophagy induction through starvation of cells has been shown to increase 
the formation of TNTs13, suggesting a correlation between these processes. Recently, we 
observed that TNT signaling induces the secretion of pro-survival cytokines4. Autophagy 
is a known regulator of cytokine signaling and this process is influenced by mitochondrial 
reactive oxygen species and/or mitochondrial DNA14.The transfer of mitochondria and 
autophagosomes from leukemic cells toward MSCs might therefore explain the release 
of supportive factors by the tumor microenvironment, as we recently reported elsewhere 
(Figure 2E)4. Interestingly, the transcription of ICAM1, a transmembrane protein involved 
in cell-cell adhesion, is known to be upregulated in response to cytokine signaling and 
reactive oxgen species15. Its transport toward MSCs may provide anchorage to facilitate 
TNT function. 
In conclusion, these data show the potential of using fluorescently labeled marker 
proteins to characterize which cellular structures are transported by TNT signaling from 
ALL cells to MSCs. Our study confirmed several known TNT cargo (i.e. mitochondria 
and transmembrane proteins)8, 9 and revealed novel structures (autophagosomes) that 
are transported through TNTs. The TNT-dependent transfer of autophagosomes and 
mitochondria from ALL cells toward MSCs might unveil an important mechanism that 
leukemic cells use to affect their microenvironment. Our study suggests that instead of 
upregulating autophagy in an indirect manner, leukemic cells transfer autophagosomes 
to MSCs in order to enhance autophagy-induced cytokine secretion. In addition, our 
study identifies autophagosomes, ICAM1 and mitochondria as important structures that 
are actively transported from leukemic cells toward their microenvironment via TNTs.
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(n = 3). (D) Graph showing the transfer of tRFP from BCP-ALL cells toward MSCs after TNT inhibition 
(grey and black bars), compared to normal co-culture conditions (white bars; n = 3; one-tailed 
t-test, paired). (E) Model of TNT signaling in the leukemic niche: 1: Leukemic cells use TNT signaling 
to transfer autophagosomes, mitochondria and ICAM1 toward MSCs in their microenvironment. 
2: Increased reactive oxygen species (ROS) and autophagy in MSCs induces the production of 
cytokines, 3: Supportive and nurturing factors are released into the tumor microenvironment, which 
induce survival and drug resistance in leukemic cells. Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01. 
See also supplemental Figure 2.
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SUPPLEMENTAL DATA
METHODS
Cell lines
BCP-ALL cell line NALM6 (B-Other) and human embryonic kidney cell line HEK293T were 
obtained from DSMZ (Braunschweig, Germany), used at low cell passages, and routinely 
verified by DNA fingerprinting. 
Isolation and characterization of MSCs
Mesenchymal stromal cells (MSCs) were isolated from bone-marrow aspirates and 
characterized as previously described13,17. In short, MSCs were confirmed to have 
multilineage potential for adipocyte, osteocyte and chondrocyte differentiation and 
characterized using positive (CD44/ CD90/CD105/CD54/CD73/CD146/CD166/STRO-1) 
and negative surface markers (CD19/CD45/CD34).
Leukemic clones containing fluorescent cellular markers
HEK293T cells were transfected with lentiviral vectors coding for tRFP-positive marker 
proteins (Cellpainter™ Organelle Markers; Origene, USA), together with the helper 
plasmids VSVG and pPAX, using X-tremegene 9 (Sigma-Aldrich; Saint Louis, USA). 
Turbo-RFP (tRFP) was added either C- or N-terminally to the marker proteins, to minimize 
its influence on protein structure (supplemental Figure 1). Lentiviral particles produced 
by the HEK293T cells were collected by harvesting supernatant for three consecutive 
days and purified using a 0.45 µm cellulose acetate filter (GE Healthcare Life Sciences, 
Buckinghamshire, United Kingdom) and ultra-centrifugation (32.000 rounds per minute 
(RPM) for 2 hours at room temperature).
BCP-ALL cells (NALM6) were transduced with a serial dilution of lentivirus to 
ensure optimal cell viability and virus transduction. Subsequently, BCP-ALL cells were 
centrifuged at 1800 RPM for 45 minutes at room temperature and incubated overnight. 
Afterwards, single cells were plated out and positive leukemic clones were selected based 
on tRFP positivity using a MACSQuant analyzer (Miltenyi Biotec, Gladbach Germany). 
The proliferation capacity of leukemic clones was confirmed to be unaffected compared 
to wildtype cells, by prolonged cell culture.
Confocal laser scanning microscopy 
Leukemic clones expressing tRFP-positive marker proteins were visualized using a confocal 
laser scanning microscope (Leica SP5). The nucleus of leukemic cells was stained using 
live cell stain “Nucblue”, according to the manufacturer’s protocol (Life Technologies, 
Breda, The Netherlands). Cells were imaged without fixation to retain optimal tRFP 
signal. Confocal images were acquired using sequential scanning of different channels 
at a resolution of 1024 x 1024 pixels in the x x y plane and 0.15 µm steps in z-direction. 
Nucblue and tRFP-positive marker proteins were excited with a 405-nm ultraviolet laser 
88 89
44
A
U
TO
PH
A
G
O
SO
M
E TRA
N
SFER V
IA
 TN
TS IN
 TH
E LEU
K
EM
IC
 N
IC
H
E
A
U
TO
PH
A
G
O
SO
M
E TRA
N
SFER V
IA
 TN
TS IN
 TH
E LEU
K
EM
IC
 N
IC
H
E
and a 561-nm Diode-Pumped Solid-State laser, respectively. Image processing was done 
with Fiji software19.
Transfer of tRFP protein markers
tRFP-positive BCP-ALL cells (NALM6) were co-cultured with tRFP-negative MSCs in 
a 4:1 ratio for 24, 48 or 72 hours with and without TNT inhibition. TNTs were inhibited 
by mechanical disruption via gentle shaking of cell cultures (250 RPM), or by physical 
separation of leukemic cells (cultured in a 3.0 µm pore-sized insert) and MSCs (cultured 
in the bottom compartment of a transwell system; Corning, New York, USA). BCP-ALL 
cells and MSCs were separated using Brilliant Violet 421 labeled anti-human CD19 
antibody (Biolegend, San Diego, USA). Median intensity of MSCs for the PE-channel was 
used as a measure of tRFP protein transfer and was determined using flow cytometry 
(BD Biosciences, California, USA; see Figure 1D for gating strategy). 
Statistical analysis
Student’s t-test was used as a statistical test and a Student’s paired t-test was used when 
applicable (indicated in figure legends). Pearson correlation testing was used to compare 
the median tRFP intensity of MSCs and BCP-ALL cells after co-culture. Error bars show as 
standard error of the mean (SEM). Sample size and statistical test methods are reported 
in the figure legends. Variance between groups that are statistically compared is similar.
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Actin, beta Actin filaments ACTB 1852 bp  N-tRFP tag 
Calreticulin Endoplasmatic reticulum CALR 1929 bp  C-tRFP tag 
Empty vector - -  C-tRFP tag 
Intercellular adhesion molecule 1 Integrin signalling ICAM1 3249 bp  C-tRFP tag 
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RAB7A, member RAS oncogene family Late endosome RAB7A 2240 bp   N-tRFP tag 
RAB11A, member RAS oncogene family Recycle endosome RAB11A 4943 bp  N-tRFP tag 
Supplemental Figure 1. Transduction of cells with lentiviral vectors encoding for 
specific cellular markers
A
B
Supplemental Figure 1. Transduction of leukemic cells with lentiviral vectors encoding for 
specific cellular markers. (A) Schematic overview of the lentiviral vector backbone in which specific 
cellular marker proteins were cloned. Two insertion sites were used in order to position the tRFP 
tag C or N-terminally. (B) Overview of the marker proteins depicting which cellular structures they 
visualize, their gene name, their length in base pairs (bp), and the position of the tRFP tag.
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Supplemental Figure 2. tRFP positivity of BCP-ALL clones differs between markers
Supplemental Figure 2. tRFP positivity of BCP-ALL clones differs between markers. Graph 
showing the median tRFP intensity of tRFP-positive BCP-ALL cells for each cellular marker (n = 3). 
tRFP signal differs between clones and therefore transfer of tRFP protein from BCP-ALL cells toward 
MSCs should be corrected for the intensity of leukemic cells.
Chapter 5ACUTE LYMPHOBLASTIC 
LEUKEMIA CELLS CREATE A LEUKEMIC 
NICHE WITHOUT AFFECTING 
THE CXCR4/CXCL12 AXIS
Bob de Rooij*, Roel Polak*, Lieke C.J. van den Berk, 
Femke Stalpers, Rob Pieters & Monique L. den Boer
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Acute lymphoblastic leukemia (ALL) is characterized by an outgrowth of malignant 
lymphoblasts that occupy the bone marrow microenvironment, where they reside 
with mesenchymal stromal cells (MSCs)1. Leukemic cells are able to disrupt the healthy 
microenvironment and create a leukemic niche that shelters malignant cells from 
elimination through cytostatic treatment and immune responses2, 3. Disrupting 
intercellular communication in this malignant microenvironment sensitizes leukemic 
cells to chemotherapeutic drugs4. Homing of ALL cells toward the bone marrow 
microenvironment is thought to be similar to that of hematopoietic stem cells (HSCs)5. 
Human CD34+ progenitor cells, are attracted by stromal cell-derived factor 1 (SDF-1/
CXCL12), a chemoattractant actively produced by MSCs in the bone marrow5, 6. CXCL12 
binds to the CXCR4 receptor. Disturbance of the CXCR4/CXCL12 axis, by treatment with 
cytokines and/or CXCR4 antagonists, mobilizes HSCs to the peripheral blood7, and shows 
promising pre-clinical results in AML patients8. Like HSCs, ALL cells have high CXCR4 
surface expression and disruption of CXCR4/CXCL12 interaction reduces ALL engraftment 
in animal models9, 10. However, in mice suffering from ALL, CXCR4/CXCL12 inhibition as 
mono-treatment did not reduce the leukemic cell number in the bone marrow9, 11. In 
addition, CXCL12 expression was remarkably downregulated in murine bone marrow 
regions of extensive ALL growth1. Likewise, CXCL12 levels in the bone marrow of patients 
diagnosed with BCP-ALL were lower compared to those in the same patients at the time 
of remission and healthy controls6. This suggests that ALL cells use additional mechanisms 
to retain a protective microenvironment.
In this study, we used an ex vivo co-culture model in which we cultured B-cell precursor 
ALL (BCP-ALL) cells with bone marrow-derived primary MSCs. Several studies show that ALL 
cells home toward the bone marrow microenvironment in a CXCR4/CXCL12-dependent 
manner1, 9, 10. We confirmed these findings in our model by assessing the migration 
of GFP-positive BCP-ALL cells (NALM6) toward MSCs, using a transwell system. MSCs 
induced migration of BCP-ALL cells by 5-16 fold compared to medium controls (p < 0.05; 
Figure 1A and supplementary Figure 1A-B). The induction of migration was correlated 
with the level of CXCL12 produced by the primary MSCs (Figure 1B). Inhibition of 
the CXCR4/CXCL12 axis with AMD3100 significantly impaired migration of BCP-ALL cells 
toward MSCs (4.5-fold reduction, p < 0.01; Figure 1C).
Next, we hypothesized that BCP-ALL cells alter the chemoattractive properties of their 
microenvironment. To address this hypothesis, GFP-negative BCP-ALL cells (NALM6) were 
cultured with MSCs in the bottom compartment of a transwell system as a model of 
the leukemic niche. Migration of GFP-positive BCP-ALL cells (NALM6) from the upper 
to the bottom compartment was determined (supplementary Figure 1A-C). GFP-positive 
BCP-ALL cells migrated significantly more toward ALL-MSC co-cultures than toward 
MSCs in mono-culture (blue bars versus grey bars, p < 0.01; Figure 1D and supplementary 
Figure 1D-E). The leukemic niche induced migration of BCP-ALL cells by 2.2-fold 
(Figure 1E, p < 0.001). Surprisingly, CXCR4 inhibition by AMD3100 did not affect 
the preferential migration of BCP-ALL cells towards the leukemic niche (2.2-fold versus 
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2.5-fold, p = 0.52, Figure 1E and supplementary Figure 1F). In addition, we compared 
CXCL12 levels in the supernatant of mono- and co-cultures of primary BCP-ALL cells 
derived from 9 different BCP-ALL cases and 4 primary MSCs. CXCL12 levels were high in 
mono-cultures of MSCs, and below detection level in mono-cultures of primary BCP-ALL 
cells (supplementary Figure 2A-B). Co-culture of primary BCP-ALL cells and MSCs did 
not increase CXCL12 levels compared to the combined levels produced in both mono-
Figure 1. ALL-MSC co-cultures induce leukemic cell migration without affecting the CXCR4/CXCL12 axis
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Figure 1. ALL-MSC co-cultures induce leukemic cell migration without affecting the CXCR4/
CXCL12 axis. (A) Graph showing the fold-change in migration of GFP-positive BCP-ALL cells 
(NALM6) toward four distinct primary bone marrow-derived MSCs compared to background 
migration toward culture medium after 48 hours in a 3.0 μm transwell system (n = 5 for each MSC; 
one-tailed t-test, unpaired). We used MSCs derived from healthy controls (MSC#1 and MSC#2) and 
MSCs derived from leukemia patients at diagnosis (MSC#3 and MSC#4), see also supplementary 
Table 3. Migration towards culture medium was used to calculate the foldchange migration. (B) 
Graph showing the secretion of CXCL12 by primary MSCs as determined using a fluorescent bead-
based immunoassay (n = 6 for each MSC). (C) Graph showing the effect of CXCR4 blockade with 
AMD3100 (10µM) on the migration of NALM6 cells toward primary MSCs after 48 hours in a 3.0 
μm transwell system (n  =  4; one-tailed t-test, paired). Migration towards culture medium was 
used to calculate the foldchange migration. For this experiment we combined the data of four 
distinct primary MSCs (MSC#1-4). (D) Graph showing the migration of NALM6 cells toward MSCs 
in mono-culture (normal niche, grey bars) or toward ALL-MSC co-cultures (leukemic niche, blue 
bars), after 48 hours in a 3.0 μm transwell system (n = 5 for each MSC; one-tailed t-test, paired). 
Migration towards culture medium was used to calculate the foldchange migration. Experiments 
were performed with MSCs from four different donors. (E) Graph showing that the leukemic 
niche affects the migration of BCP-ALL cells independent of CXCR4/CXCL12 signaling. Migration 
of NALM6 cells toward N6-MSC co-cultures (leukemic niche, blue bars) is compared to migration 
toward MSC mono-cultures (normal niche, grey bars) in absence or presence of AMD3100 (10 µM) 
after 48 hours using a 3.0 µm transwell system (n = 4; one-tailed t-test, paired). For this experiment 
we combined the data of four distinct primary MSCs (MSC#1-4). Data is shown as fold induction 
compared to migration towards MSC mono-culture. (F) Plots showing the secreted levels of CXCL12 
by primary BCP-ALL cells and MSCs in mono-culture (circles represent the sum of cytokine secretion 
in mono-culture of BCP-ALL and mono-culture of MSC) compared to ALL-MSC co-culture (squares). 
Data was determined using a multiplexed fluorescent bead-based immunoassay. Boxes represent 
p25-p75 intervals. (G) Graph showing the migration of umbilical cord blood-derived healthy CD34+ 
progenitor cells after 48 hours in a 3.0 μm transwell system. Bars represent migration toward culture 
medium, NALM6 cells, MSCs and NALM6-MSC cultures ( n = 3; one-tailed t-test; paired). Migration 
towards MSC mono-culture was used to calculate the foldchange migration. Data are means ± 
SEM; * p ≤ 0.05, HPC = hematopoietic progenitor cell. (H-I) Primary MSCs (experiments performed 
with MSC#1 and MSC#3) were allowed to migrate to the other side of a 8.0 μm transwell insert 
for 16 hours. Cells were fixed and subsequently stained with crystal violet. MSCs migrated toward 
a bottom compartment containing culture medium, MSCs or BCP-ALL cells (REH). The amount of 
migrated cells was measured by spectrophotometry of crystal violet stained cells. (H) Graph showing 
the migration of primary MSCs. Migration towards medium was used to calculate the foldchange 
migration (n = 4; one-tailed t-test; paired). (I) Graph showing the migration of primary MSCs toward 
REH cells (BCP-ALL, black bars) or REH-MSC co-cultures (leukemic niche, blue bars) (n = 4; one-
tailed t-test, paired). Data are relative to control condition without BCP-ALL cells (medium-only or 
MSC-only control). Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, N6 = NALM6. 
See also supplementary Figures 1-3.
cultures (Figure 1F). These results suggest that BC-PALL cells create a leukemic niche that 
attracts leukemic cells in a CXCR4/CXCL12 independent manner. 
Next, we assessed the migration of healthy CD34+ hematopoietic progenitor cells 
(HPCs) toward primary MSCs cultured with or without BCP-ALL cells. As expected, CD34+ 
HPCs migrated more abundantly toward MSCs than to control medium without MSCs 
(1.8-fold, p < 0.05; Figure 1G). However, migration of CD34+ HPCs toward ALL-MSC 
co-cultures was significantly reduced compared to migration toward MSCs in mono-
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Figure 2.  Chemokines inducing the CCR4 and CXCR1/2 axes are upregulated in the BCP-ALL niche
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Figure 2. Chemokine inducing the CCR4 and CXCR1/2 axes are upregulated in the BCP-ALL 
niche. (A) Plots showing the secretion of CCL2/MCP-1 and CCL22/MDC by primary MSCs (n = 4) 
and primary BCP-ALL cells (n = 10) in mono-culture (circles represent the sum of cytokine secretion 
in mono-culture of BCP-ALL and mono-culture of MSC) compared to ALL-MSC co-cultures (squares). 
Data was obtained using a multiplexed fluorescent bead-based immunoassay. Boxes represent 
p25-p75 intervals. Raw data was logarithmically transformed to obtain a normal distribution of 
the data and upregulation of cytokines was tested using a one-tailed paired t-test * p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001. (B) Plots showing the serum levels of CCL2/MCP-1 and CCL22/MDC in 
bone marrow aspirates from healthy controls (n = 7, circles), from untreated BCP-ALL patients at 
diagnosis (n  =  10, blue squares) and from BCP-ALL patients after induction treatment (n  =  10, 
triangles; lines indicate paired samples). Data was obtained using a multiplexed fluorescent bead-
based immunoassay in which we measured the levels of 64 cytokines. Healthy (circles) and leukemic 
samples (blue squares) were compared using a two-tailed unpaired t-test. Leukemic samples 
before and after induction therapy (blue squares versus triangles) were compared using a one-
tailed paired t-test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (C) Same as (A) for CXCL8/IL-8 and 
CXCL1/GRO secretion. (D) Plots showing the serum levels of GRO/CXCL1 and CXCL8/IL-8. See also 
supplementary Figure 2 and 4 and supplementary Table 1 and 2.
cultures (20% reduction, p < 0.05; Figure 1G). In addition, we assessed the migratory 
behavior of healthy MSCs toward ALL-MSC co-cultures. We performed a transwell 
migration assay in which primary MSCs were allowed to migrate toward BCP-ALL cells or 
other MSCs in the bottom compartment. We observed that MSC migration was induced 
toward other MSCs compared to control medium (p  <  0.05; Figure 1H). Strikingly, 
MSCs also actively migrated to BCP-ALL cells illustrating that BCP-ALL cells are able 
to recruit MSCs (p  < 0.001; Figure  1H and supplementary Figure 3A). However, MSC 
migration was significantly inhibited toward the leukemic niche (ALL-MSC co-cultures) 
compared to a bottom compartment containing only BCP-ALL cells (2-3 fold reduction, 
p < 0.001, Figure 1I and supplementary Figure 3B-C). Interestingly, increasing 
the amount of ALL cells (up to 16fold) in ALL-MSC co-cultures did not re-induce MSC 
migration (Figure 1I). These results show that ALL-MSC co-cultures efficiently attract 
leukemic cells, but reduce migration of healthy CD34+ HPCs and primary MSCs, suggesting 
that ALL-MSC co-cultures produce chemokines that specifically attract BCP-ALL cells. 
To address which cytokines/chemokines may be altered in the leukemic niche, we 
quantified the levels of 64 cytokines known to be important in immunology/hematology 
in the supernatant of ex vivo co-cultures of patient-derived BCP-ALL cells (n  =  10, 
representing major BCP-ALL subgroups) and MSCs (n = 4) (supplementary Table 1). 
Cytokine/chemokine profiles of mono-cultures of primary BCP-ALL cells and primary MSCs 
are depicted in supplementary Figure 2. Cocu-ltures of BCP-ALL cells with MSCs revealed 
the induction of unique secretion patterns per patient. These patterns were similar for 
different sources of MSC, i.e. MSCs obtained at the time of leukemia and those obtained 
from healthy controls.  The unique profile per BCP-ALL patient suggests that leukemic 
cells govern the observed cytokine secretion (Figure 2, supplementary Figure 4A-B and 
supplementary Table 2). These unique cytokine/chemokine profiles suggest the need 
for patientspecific approaches to disrupt the leukemic niche. However, we also found 
recurrently induced signaling pathways. All ALL-MSC co-cultures showed increased levels 
of CCL2/MCP-1 and/or CCL22/MDC (Figure 2A), both ligands for the CCR4 receptor. 
This chemokine receptor is implicated in T cell leukemia and lymphoma, but has not yet 
been implicated as an important factor in BCP-ALL13. In addition, analysis of previously 
published microarray-based gene expression data showed that CCR4 expression levels 
in pediatric ALL cells were significantly higher compared to healthy hematopoietic cells 
(Supplementary Figure 4C).
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Further, we observed recurrent induction of CXCL8/IL-8 and CXCL1/GRO secretion, 
ligands of the CXCR1 and CXCR2 receptor. CXCR1/2 ligands were induced by BCP-ALL 
cells from six out of ten patients (Figure 2C). In contrast to CCR4 expression, CXCR1 and 
CXCR2 expression levels were lower in pediatric ALL compared to healthy hematopoietic 
cells (supplementary Figure 3C). 
We validated the cytokine/chemokine patterns identified in our co-culture model 
using serum derived from bone marrow aspirates from 10 ALL patients at diagnosis. We 
compared the cytokine/chemokine patterns in these samples with serum obtained from 
bone marrow aspirates of the same patients taken at the end of induction chemotherapy. 
At this stage of treatment the patients were in remission. Furthermore, we used bone 
marrow aspirates of 7 healthy controls to analyze cytokine/chemokine patterns of 
the healthy niche. Levels of the CCR4 ligand CCL2/MCP-1 were significantly higher in 
the bone marrow of untreated, newly diagnosed BCP-ALL patients compared to healthy 
controls (2.0-fold increase, p < 0.01; Figure 2B). Interestingly, after induction therapy, 
the CCL2/MCP-1 levels in the bone marrow of ALL patients decreased to levels observed 
in healthy controls (2.2 fold decrease, p < 0.01; Figure 2B). This suggests that the induced 
CCL2/MCP-1 levels at diagnosis are causally linked to the presence of leukemic cells. 
CCL22/MDC levels were similar between BCP-ALL patients and healthy controls 
(Figure 2B). Like CCL2/MCP-1, CXCL1/GRO levels were also increased in the bone marrow 
of BCP-ALL patients (2.3-fold increase, p < 0.05; Figure 2D) and CXCL8/IL8 levels showed 
a trend towards upregulation (2.5fold, p = 0.052; Figure 2D). Similar to CCL2/MCP-1 
levels, the secreted levels of these CXCR1/2 ligands were significantly reduced after 
induction chemotherapy (2.3 fold and 3.1-fold respectively, p < 0.05; Figure 2D). These 
data implicate that CCR4 and CXCR1/2 signaling are important in the bone marrow 
of BCP-ALL patients and suggest that CCR4 inhibition (e.g. by mogamulizumab(14)) 
or CXCR1/2 inhibition might be an alternative or additional way to disrupt 
the BCP-ALL niche
In conclusion, our data indicate that the BCP-ALL niche is highly potent in attracting 
BCP-ALL cells and repelling the influx of healthy hematopoietic cells and MSCs in 
a CXCL12 independent manner. Instead, we show the recurrent induction of CCR4 and 
CXCR1/2 ligands by BCP-ALL cells in the leukemic niche (Figure 3). Our data point to 
CCR4 and CXCR1/2 as valuable future therapeutic targets to interfere with the leukemic 
niche in ALL. 
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Figure 3. Model of the self-reinforcing BCP-ALL niche. Proposed model for the formation 
of a leukemic niche by BCP-ALL cells. BCP-ALL cells actively migrate toward MSCs in a CXCL12 
dependent manner. Simultaneously, MSC migration is induced by BCP-ALL cells. When BCP-ALL cells 
and MSCs are in close proximity, a leukemic microenvironment is created that specifically attracts 
other BCP-ALL cells and inhibits the migration of MSCs and healthy CD34+ cells. This process is 
CXCR4/CXCL12 independent and is characterized by the secretion of patient-unique cytokines.
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SUPPLEMENTARY DATA
MATERIALS AND METHODS
Cell lines and reagents
B-cell precursor ALL (BCP-ALL) cell lines, NALM6 (B-Other) and REH (TEL-AML1), were 
obtained from DSMZ (Braunschweig, Germany), used at low cell passages, and routinely 
verified by DNA fingerprinting. Cell lines were cultured in RPMI-1640 medium containing 
10% fetal calf serum (FCS), 1% penicillin-streptomycin at 37 °C and 5% CO2.
Isolation of primary BCP-ALL leukemic blasts from patients
Primary BCP-ALL leukemic blasts were isolated from patients as described earlier (Polak et 
al. Blood 2015). In short, mononuclear leukemic cells were collected from bone marrow 
aspirates obtained from children with newly diagnosed BCP-ALL prior to treatment. All 
samples used in this study contained > 95% leukemic blasts.
Isolation and characterization of primary MSCs
Primary MSCs were isolated and characterized using positive (CD44/ CD90/ CD105/ 
CD54/ CD73/ CD146/ CD166/ STRO-1) and negative surface markers (CD19/ CD45/ 
CD34)(8). In addition multilineage potential was confirmed as described earlier (Polak 
et al. Blood 2015).
Isolation of CD34+ cells
CD34+ cells were obtained from umbilical cord blood using the Direct CD34 Progenitor 
Cell Isolation kit, human (Miltenyi Biotec, Gladback, Germany). CD34+ cells were 
positively selected by magnetic microbeads using the MACS LS column (Miltenyi Biotec) in 
combination with a MACS separator (Miltenyi Biotec). The purity of the isolated cells was 
confirmed by flow cytometry using the CD34-PE fluorescent antibody (BD Pharmingen, 
San Diego, USA).
Collection of bone marrow aspirates
Serum samples of bone marrow aspirates were collected from children with ALL at initial 
diagnosis and after completion of two courses of chemotherapy according to the ALL-10 
protocol of the Dutch Childhood Oncology Group (day 79 after start of treatment) as 
previously described (van den Berk et al. Br J Haemat 2014). This study was approved 
by the Institutional Review Board and informed consent was obtained from parents 
or guardians.
Cell viability assays
Cell viability assays of primary material was performed as earlier described (Polak 
et al. Blood 2015). In short, primary patient cells (1 x 106 cells) were co-cultured with or 
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without primary stromal cells (5 x 104) for five days in a 24-well plate at 37 °C and 5% 
CO2. Stromal cells were allowed to attach prior to the start of an experiment. Before 
the start of each experiment, leukemic cells were screened for CD19 positivity (Brilliant 
Violet 421 anti-human CD19 antibody), which was used to discriminate leukemic cells 
from CD19neg MSCs. The percentage of viable leukemic cells was determined after 5 
days of culture by staining with Brilliant Violet 421 anti-human CD19 (Biolegend), FITC 
Annexin V (Biolegend), and Propidium Iodide (PI; Sigma), after which the percentage of 
AnnexinVneg/PIneg/CD19pos cells within the MSC negative fraction was determined by flow 
cytometry (BD Biosciences). 
Multiplexed fluorescent bead-based immunoassay (Luminex)
Primary leukemic cells were co-cultured with different sources of primary MSCs for 
5 days at 37°C and 5% CO2. Supernatant was collected upon which the viability of 
leukemic cells was assessed as described above. The concentration of 64 known 
cytokines/chemokines in these supernatants was analyzed using fluorescent bead-based 
immunoassay (Luminex Human Cytokine/Chemokine Panel I and II; Merck Millipore) 
according to the manufacturer’s protocol.
Serum of bone marrow aspirates of leukemia patients or healthy controls were used 
to determine the concentration of 64 known cytokines/chemokines using the same 
fluorescent bead-based immunoassay (Luminex Human Cytokine/Chemokine Panel I and 
II; Merck Millipore) according to the manufacturer’s protocol
BCP-ALL migration assay
BCP-ALL migration experiments were performed using RPMI 10% FCS at 37°C and 5% 
CO2. 5 x 10
4 primary MSCs and 2 x 105 BCP-ALL cells were cultured either separate or in 
co-culture in the lower compartment of a transwell in a volume of 750 µL for 24 hours 
prior to the start of the experiment. At the start of experiment, 4 x 105 NALM6-GFP cells 
in a volume of 250 µL were added to the upper compartment of a 6.5 mm diameter 
transwell system (Corning, NY, USA) with a pore size of 3.0 µm. Cells were allowed to 
migrate for 48 hours. At the end of experiment, transwells were removed and cells in 
the bottom compartment were harvested and stained with DAPI (Life Technologies). DAPI-/
GFP+ cells were used as a measure for cell migration and quantified by flow cytometry 
using a MACSQuant analyzer (Miltenyi Biotec, Gladbach, Germany).
CD34+ migration assay
Experiments were performed using either RPMI Dutch Modified 15%FCS or Iscove modified 
Dulbecco medium (Gibco) containing 10% FCS, 50μM β-mercaptoethanol, 1% penicillin-
streptomycin, 2mM glutamine, stem cell factor (SCF; 50ng/mL; Peprotech) and fms-like 
tyrosine kinase-3 ligand (Flt3L; 50 ng/mL; Peprotech) at 37°C and 5% CO2. Primary MSCs 
(5 x 104) and NALM6-GFP cells (2 x 105) were cultured either separate or in co-culture 
in a volume of 750 µL for 24 hours prior to start of experiment (bottom compartment). 
At the start of experiment, 5 x 105 CD34+ cells in a volume of 250 µL were added to 
the top chamber of a 3.0 µm transwell system (Corning, NY, USA) and allowed to migrate 
for 48 hours at 37°C and 5% CO2. At the end of experiment, transwell inserts were 
removed upon which the cells in the bottom compartment were harvested and stained 
with Propidium Iodide (PI; Sigma) and Brilliant Violet 421 anti-human CD45 antibody 
(Biolegend). PI-/GFP-/CD45+ cells were quantified by flow cytometry using a MACSQuant 
analyzer (Miltenyi Biotec, Gladbach, Germany).
MSC migration assay
Experiments were performed using DMEM medium containing 5% FCS, 1% penicillin-
streptomycin at 37°C and 5% CO2. REH cells (0.1 – 1.6 x 10
6) and primary MSCs 
(5 x 104) were cultured either separate or in co-culture in a volume of 750 µL for 48 
hours prior to start of experiment. At the start of experiment, 5 x 104 MSCs were added 
to the top chamber of a 8.0 µm transwell system (Corning) and allowed to migrate 
through the membrane overnight (12-16 hours). Non-migrated cells were removed from 
the upper side of the transwell insert using a cotton swab. Cells that migrated through 
the membrane insert were fixed using 10% Formalin (Sigma) for 10 minutes, washed with 
PBS and stained for 30 minutes with Crystal violet at room temperature. Images were 
captured using a Leica DM IL microscope mounted with a Leica DFC430C camera (Leica, 
Germany). Next, Crystal violet contained by MSCs was dissolved in 150 µL methanol, 
quantified by spectrophotometer using 540-570 nm wavelength settings (Versamax, San 
Francisco) and used as a measure of migration.
Statistical analysis
We used the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl) to 
visualize gene expression data in Figure 4 and performed one way analysis of variance 
(ANOVA). For other statistics, Student’s t-test was used and a Student’s paired t-test was 
used when applicable. Bar graphs represent the mean of biological replicates. Error bars 
show standard error of the mean (SEM).
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SUPPLEMENTARY FIGURES
Supplementary Figure 1. BCP-ALL cells create a self-reinforcing niche with mesenchymal stromal cells
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Supplementary Figure 1. ALL-MSC co-cultures induce leukemic cell migration. (A) Schematic 
overview of the experimental conditions used for experiments shown in  Figure 1D-E. The migration 
of GFP-positive NALM6 cells is measured toward: culture medium (Control), primary MSCs (Normal 
Niche) or GFP-negative ALL-MSC co-cultures (Leukemic Niche). (B) Representative microscope 
images depicting migrated GFP-positive NALM6 cells after 48 hours in a 3.0 μm transwell system. 
GFP-positive NALM6 cells were allowed to migrate toward a bottom compartment containing 
either culture medium, GFP-negative NALM6 cells or primary MSCs (n = 4). (C) Gating strategy 
for quantification of migrated GFP-positive NALM6 cells. (D) Representative flow cytometry plots 
showing the migration of GFP-positive NALM6 cells toward GFP-negative NALM6 cells, MSCs and 
GFP-negative ALL-MSC co-cultures. (E) Representative microscope images showing the migration 
of GFP-positive NALM6 cells toward GFP-negative ALL-MSC co-cultures (right panel) or migration 
to a bottom compartment containing only MSCs (left panel; n = 4). No LCs = no leukemic cells in 
the bottom compartment. (F) Graph showing the effect of CXCR4 inhibition by AMD3100 (10 µM) 
on migration of NALM6 cells towards MSC mono-cultures (normal niche, grey bars) and ALL-MSC 
co-cultures (leukemic niche, blue bars). Migration towards culture medium is used to calculate 
the foldchange migration. CXCR4 inhibition decreases migration of NALM6 cells towards the healthy 
and leukemic niche in a similar manner. However, the leukemic niche still induces migration of 
NALM6 cells in the presence of AMD3100. Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, N6 = NALM6. See also Figure 1.
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Supplementary Figure 2. Cytokine secretion of primary MSCs and BCP-ALL cells in mono-
culture. (A) Graph showing the cytokine production of MSCs from four donors after 5 days of 
mono-culture. (B) Graph showing the cytokine production of BCP-ALL cells from 10 different donors 
after 5 days of mono-culture. Data was obtained using a multiplexed fluorescent bead-based 
immunoassay. Secreted levels of 64 cytokines/chemokines were analyzed. Cytokines/chemokines 
that were not detected in mesenchymal stromal cells or ALL cells were not depicted in this figure. < 
LOD = below limit of detection. See also Figure 2.
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Supplementary Figure . BCP-ALL cells recruit MSCs and stop recruiting after the niche is established 
C Control
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- MSC
+ MSC
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8.0µm BCP-ALL (REH)
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B
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Supplementary Figure 3. BCP-ALL cells recruit MSCs and stop recruiting after the leukemic 
niche is established. (A) Images of a representative experiment showing MSCs that migrated to 
the other side of a 8.0 μm transwell insert for 16 hours. Cells were fixed and subsequently stained 
with crystal violet. Images show MSCs migrated toward a bottom compartment containing culture 
medium, MSCs or BCP-ALL cells (REH) (n = 4). (B) Schematic overview of experimental conditions 
used in Figure 1I and supplementary Figure 2C. (C) Images of a representative experiment showing 
that MSCs migrate to the other side of a 8.0 μm transwell insert for 16 hours toward an increasing 
amount of BCP-ALL cells (REH) in mono-culture (upper panels) or in co-culture with MSCs (MSC + 
REH; lower panels). See also Figure 1.
Supplementary Figure 4. Chemokines and receptors upregulated in the BCP-ALL niche. 
(A) Plots showing the secretion of CXCL10 (IP10) by primary MSCs and primary BCP-ALL cells in 
mono-culture (circles represent the sum of cytokine secretion in mono-culture of BCP-ALL and 
mono-culture of MSC) compared to ALL-MSC co-cultures (squares). Data was obtained using 
a multiplexed fluorescent bead-based immunoassay. Boxes represent p25-p75 intervals. Raw data 
was logarithmically transformed to obtain a normal distribution of the data and upregulation of 
cytokines was tested using a one-tailed paired t-test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (B) Plot 
showing the serum levels of CXCL10 (IP10) in bone marrow aspirates from healthy controls (n = 7, 
circles), from untreated BCP-ALL patients at diagnosis (n = 10, blue squares) and from BCP-ALL 
patients after induction treatment (n  =  10, triangles; lines indicate paired samples). Data was 
obtained using a multiplexed fluorescent bead-based immunoassay in which we measured the levels 
of 64 cytokines. Healthy (circles) and leukemic samples (blue squares) were compared using a two-
tailed unpaired t-test. Leukemic samples before and after induction therapy (blue squares versus 
triangles) were compared using a one-tailed paired t-test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (C) 
Gene expression levels of the CCR4, CXCR1, CXCR2 and CXCR3 receptors in healthy hematopoietic 
cells (Andersson et al. BMC Med Genomics. 2010) and pediatric ALL cells (Den Boer et al. Lancet 
Oncol. 2009). Data was visualized using R2: microarray analysis and visualization platform. (D-E) 
Graphs showing that the increase in patient-specific cytokines was not the effect of induced cellular 
survival in ALL-MSC co-cultures. (D) Graph showing the viability of leukemic cells from patient 
Supplementary Figure 4. Chemokines and receptors upregulated in the BCP-ALL niche 
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ALL#4 cultured in absence or in presence of primary MSCs. (E) Plots showing the secretion of 
cytokines by BCP-ALL cells from patient ALL#4 in mono-culture (grey circles) and the secretion of 
cytokines by ALL#4 cells in ALL-MSC co-culture corrected for the secretion of MSCs (grey boxes). 
The dashed boxes indicate significantly upregulated cytokines shown in Figure 2. See also Figure 2.
SUPPLEMENTARY TABLES
Supplementary Table 1. Cytokine  and chemokine  screening panel
Cytokine tested Receptor
VEGF VEGFR
sCD40L C40; αIIbβ3; α5β1
EGF EGFR
Eotaxin CCR2; CCR3; CCR5
FGF-2 FGFR1
Flt-3 ligand Flt-3
Fractalkine CX3CR1
G-CSF GCSFR
GM-CSF GMCSFR
GRO CXCR2
IFNα2 IFNAR
IFN-γ IFNGR1; IFNGR2
IL-1α IL1R
IL-1β IL1R
IL-1ra IL1R
IL-2 IL2R
IL-3 IL3R
IL-4 IL4R
IL-5 IL5R
IL-6 CD126 and CD130 complex
IL-7 IL7R
IL-8 CXCR1; CXCR2
IL-9 IL9R
IL-10 IL10R1-IL10R2 complex
IL-12 (p40) IL12R
IL-12 (p70) IL12R
IL-13 IL13R
IL-15 IL15RaR
IL17A IL17R
IP-10 CXCR3
MCP-1 CCR2 and CCR4
MCP-3 CCR2
MDC (CCL22) CCR4
MIP-1α CCR1
MIP-1β CCR1;CCR5
Supplementary Table 1. (continued)
Cytokine tested Receptor
PDGF-AA PDGFR
PDGF-AB/BB PDGFR
RANTES CCR5
TGF-α EGFR
TNF-α TNFR1
TNF-β LTB
TSLP CRLF2 and IL7-R complex
6Ckine CCR7
BCA-1 CXCR5
CTACK CCR10
ENA-78 CXCR2
Eotaxin-2 CCR3
Eotaxin-3 CCR3
I-309 CCR8
IL-16 CD4
IL-20 IL20R
IL-21 IL21R
IL-23 IL23R
IL-28A IL28R
IL-33 IL1RL1
LIF LIFR
MCP-2 CCR1; CCR2a; CCR5
MCP-4 CCR2; CCR3; CCR5
MIP-1d CCR1; CCR3
SCF c-Kit
CXCL12 CXCR4; CXCR7
TARC CCR4
TPO CD110
TRAIL TRAILR-complex
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Supplementary Table 3. Primary mesenchymal stromal cells used in this study
Name Derived from Subtype
MSC #1 Healthy BM -
MSC #2 Healthy BM -
MSC #3 Leukemic BM B-Other
MSC #4 Leukemic BM ETV6-RUNX1
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CANCER IS A DISEASE OF BOTH INTRINSICALLY AND 
EXTRINSICALLY MODIFIED CELLS
Historically, research on cancer cells has been focused on identifying intrinsic alterations 
that separate these cells from their healthy counterparts. At the end of the 19th century, 
David von Hansemann discovered that cancer cells underwent aberrant cell divisions 
that deregulate the chromatin content1. He hypothesized that these alterations were 
responsible for the behavior of cancer cells, although the tools at that time did not allow 
him to investigate these mitotic anomalies in more depth. As technologies advanced, 
a chromosomal abnormality was identified that was consistently present in cancer 
cells. Researchers discovered an exchange of genetic material between chromosome 9 
and chromosome 22 called the BCR-ABL1 translocation, or Philadelphia chromosome, 
which is often found in chronic myeloid leukemia (CML) but also in B  cell precursor 
acute lymphoblastic leukemia (BCP-ALL) cells2,3. The BCR-ABL1 fusion protein displays 
constitutive kinase activity and drives a malignant cellular phenotype4. The identification 
of an abnormality discriminative for leukemic cells presented an opportunity to develop 
cancer-specific treatment. It led to the development of imatinib, a tyrosine-kinase inhibitor 
that releases the BCR-ABL1 fusion protein from its activated oncogenic state. Survival 
of CML patients has improved significantly since the FDA approval of imatinib5. This is 
an example how genetic alterations which drive the phenotype of cancer cells can be 
targeted by specific drugs. It represents the dominant view in oncology today that cancer 
cells are separate entities which are driven by intrinsic (epi)genetic alterations. 
There is also evidence that cancer cells do not function as separate entities but are 
dependent on their cellular context. As early as 1889, physician Stephen Paget noticed 
that when cancer cells spread through the body, they have a propensity to find shelter in 
specific organs. He discussed this in his “seed and soil” hypothesis in which he compared 
the outgrowth of cancer cells to those of plant seeds. Paget stated: “When a plant goes 
to seed, its seeds are carried in all directions. But they can only live and grow if they fall on 
congenial soil6.” Similarly, cancer cells need a specific environment to thrive in. This was 
supported by his observations that breast cancer metastases were more prone to grow 
out of the liver than other organs, even those with similar blood flow6. While the site of 
tumor growth is important, there are even observations of cancer cells that are completely 
‘re-educated’ by their microenvironment. Mouse blastocysts injected with tetracarcinoma 
cells developed into healthy mice without cancer7. Interestingly, the ‘former’ cancer cells 
were still present but now performed healthy cell functions in multiple tissues7. These 
observations show that cells do not act like independent entities, but rather function as 
a system that is driven by highly complicated communication mechanisms. Hence, cancer 
is more accurately described as a disease of both intrinsically and extrinsically altered 
cells. The influence of cells surrounding tumor cells, or the tumor microenvironment, 
is an emerging field of leukemia research. The leukemic microenvironment has been 
shown to play a major role in conferring chemotherapy resistance and to be critical 
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in leukemogenesis8,9. Cytokines and other soluble factors, as well as direct cell-cell 
interactions, are thought to be important for this process10. However, we lack insight 
into how the crosstalk between leukemic cells and their microenvironment is regulated. 
This is why we were intrigued by the discovery of a new signaling module in eukaryotic 
cells: tunneling nanotubes (TNTs)11. TNTs are thin membrane protrusions capable of 
transporting a multitude of signaling molecules between distant cells. Tumor cells might 
use TNTs to influence surrounding cells and concomitantly induce cell intrinsic changes. 
Therefore we investigated the presence and importance of TNTs in the leukemic niche.
DISCOVERY OF TNT SIGNALING BETWEEN ALL CELLS AND MSCS
A few years after Rustom and colleagues identified TNTs in eukaryotic cells for the first 
time11, Sowinski et al. showed that T lymphocytes could connect using TNTs, presenting 
a route for HIV-1 tranmission12. At that time there were no studies investigating TNT 
signaling in leukemia, and therefore we tried to recapitulate these findings using 
malignant B lymphocytes in chapter 2. We observed that BCP-ALL cells connect via TNTs 
and actively exchange lipophilic structures. Next, we visualized TNT formation between 
BCP-ALL cells and mesenchymal stromal cells (MSCs). MSCs are one of the most abundant 
and important cells in the bone marrow, where BCP-ALL cells create a leukemic niche13,14. 
Surprisingly, the amount of TNTs formed between BCP-ALL cells and MSCs far surpassed 
that of TNTs between leukemic cells. Also, this signaling was mostly unidirectional: from 
leukemic cells toward MSCs. To assess the functional effects of TNT signaling, we used 
a combination of three experimental setups: 1) reducing TNT formation through actin 
inhibition11, 2) mechanical disruption of TNT connections through gentle shaking of cell 
cultures12,15, and 3) prevention of TNT formation by physically separating leukemic cells 
(cultured in a 3.0 µm pore-sized insert) and MSCs (cultured in the bottom compartment 
of a transwell system)12,16. None of these setups specifically inhibits TNTs and their effects 
on other cellular signaling modules are depicted in Table 1. However, by combining 
these experimental setups we were able to assess the effect of TNT signaling. In these 
experiments, we observed that BCP-ALL cells actively modulate their microenvironment 
using TNTs, causing the release of pro-survival cytokines and, subsequently, an increase 
in survival and resistance to chemotherapeutic drugs. Disruption of TNTs inhibited 
this cytokine release, decreased the survival benefit that MSCs provide to BCP-ALL 
cells, and sensitized BCP-ALL cells to the important anti-leukemic drug prednisolone. 
These data provide a new concept to target the leukemic niche in B-cell acute 
lymphoblastic leukemia.
FINDING NOVEL COMPOUNDS THAT INHIBIT TNT SIGNALING
TNT signaling between BCP-ALL cells and MSCs was discovered using ex vivo cultures of 
primary patient material. We wanted to translate these findings to in vivo models, but 
unfortunately, no agents were available that induce specific inhibition of TNTs. To identify 
novel TNT inhibitors, we created a system that accurately measures TNT signaling from 
BCP-ALL cells toward MSCs in chapter 2. We quantified TNT signaling by using lipophilic 
carbocyanine dyes which stain organelles and membrane components actively transported 
by TNTs11. It is important to note that these lipophilic dyes can also be exchanged by 
extracellular vesicles (ECVs). However, using a 3.0 µm pore-sized transwell system that 
allows the transfer of ECVs but abrogates all direct cell contact, we observed that dye 
transfer was inhibited by 500fold. This means that > 99.99% of the observed lipophilic 
dye transfer is caused by TNT signaling. Therefore, using flow cytometry to measure 
the lipophilic dye transfer from BCP-ALL cells toward MSCs is an accurate method to 
measure TNT activity. Quantifying dye transfer between cells is also performed in numerous 
other studies11,12,17-20. A different method is to count the frequency of TNTs in fixated cell 
cultures. This reveals information about TNTs present during fixation, but not of those 
that formed and disappeared prior to fixation. Counting TNTs is especially problematic 
when investigating compounds that induce apoptosis. In these cases, a reduction in TNTs 
after drug exposure might be caused by a lack of cells to form TNTs. It is impossible to 
exclude the possibility that TNTs were abundant and highly active prior to fixation. In 
contrast, flow cytometric analysis of lipophilic dye transfer quantifies the accumulation 
of TNT activity in time. Therefore we used this system to test the effect of compounds on 
TNT signaling between BCP-ALL cells and MSCs in chapter 3. Since TNTs are cytoskeletal 
structures, we investigated a large range of tubulin and actin inhibitors. Inhibition of 
microtubules did not negatively affect TNT signaling but rather increased lipophilic dye 
transfer from BCP-ALL cells toward MSCs. The finding that these drugs induce TNT 
signaling possible uncovers a rescue mechanism used by leukemic cells in response to 
tubulin treatment. In addition, it shows that inducing apoptosis is not sufficient to inhibit 
TNT signaling in a dye transfer based co-culture system. Next, we investigated the ability of 
11 actin disrupting molecules to inhibit TNT signaling. Actin polymerization inhibitors are 
often used to inhibit TNT formation and we confirmed their efficacy using four different 
compounds21-25. The effect of other classes of actin disrupting molecules on TNT signaling 
are unknown. Disrupting the actin nucleation proteins Arp2/3 and formins26,27, which are 
Table 1. Off-target effects of TNT inhibition. Table showing how actin inhibitors, mechanical disruption 
(shaking), or separating cells with a transwell system affect intercellular communication mechanisms 
other than TNTs. Blank cells represent no effect. Combining TNT inhibitory setups is crucial to assess 
the effect of TNT signaling.
Actin inhibition Shaking Transwell
Tunneling nanotubes inhibition inhibition inhibition
Soluble factors
Extracellular vesicles inhibition
Integrins stimulation inhibition
Gap junctions inhibition
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responsible for providing a stable start point for actin monomers28,29, strongly reduced 
TNT signaling. Interestingly, affecting the plasticity of actin polymers by cucurbitacin E30 
and jasplakinolide31,32 also strongly interfered with TNT signaling. These observations 
show that TNT signaling is driven by the interplay of fundamental actin regulating 
processes. Moreover, combining actin disassembly and actin nucleation or polymerization 
inhibitors increased TNT disruption in a synergistic-like manner. These findings provide 
new targets for TNT inhibition and increase our knowledge on the molecular mechanisms 
regulating TNTs.
THE TOXICITY OF ACTIN INHIBITORS
Disrupting the cytoskeleton as anti-cancer treatment was serendipitously discovered 
during the study of Vinca alkaloids as antidiabetics33,34. These agents interfere with 
microtubules which regulate critical steps in cell division. While very effective these drugs 
induce significant side effects including peripheral neuropathy35, and cardiovascular and 
thromboembolic events36,37. Nevertheless, it has been argued that tubulin inhibitors 
represent the most successful class of anti-cancer agents thus far, and they will likely 
remain important even as more selective drugs are developed25,34,38. Our data shows that 
TNT signaling is abrogated by multiple classes of actin inhibitors and the cytotoxic effects 
of these compounds were investigated in chapter 3. Healthy mononuclear cells were more 
resistant to actin inhibition than BCP-ALL cells, while MSCs and CD34+ hematopoietic 
progenitor cells (HPCs) were also affected. These observations show that actin inhibitors 
might be an important novel class of anti-leukemic agents that act in a cytotoxic manner 
and disrupt TNT signaling. In addition, the potential off-target effects of actin inhibitors 
demonstrate that attacking the cytoskeleton should be done with great caution.
TUNNELING NANOTUBE STRUCTURE AND SIGNALING DEPEND 
ON THE CELL TYPE
A common hurdle for TNT research is the large diversity in TNT function and morphology 
across cells. For example, macrophages propagate calcium fluxes through TNTs while T 
cells do not12,39. There is a great variety in the length, width, and lifespan of TNTs, and 
some have been reported to contain tubulin11,12,17,39. Adding to the complexity, two forms 
of de novo TNT formation have been observed (Figure 1). TNTs can protrude from one cell 
and actively elongate towards a distant cell (Figure 1A), or appear after the dislodgement 
of two connecting cells (Figure 1B). Using live confocal microscopy, we observed that ALL 
cells form TNTs with MSCs after dislodging in chapter 2. Importantly, there are three 
TNT characteristics identical across cell types. All TNTs contain polymerized actin, connect 
distant cells without adhering to the culture bottom, and actively transport molecules 
between cells40. The nanotubular structures between ALL cells and MSCs display all three 
characteristics. In chapter 2 and 3 we observed that TNTs in the leukemic niche actively 
transport lipophilic molecules. In chapter 4 we further elucidated the identity of those 
molecules. To this aim, we ectopically expressed fluorescent proteins that are markers 
for specific cellular structures in ALL cells. Our results indicate that actin, endoplasmatic 
reticulum, adhesion molecule ICAM1, autophagosomes, mitochondria, and endosomes 
are contact-dependently transferred from leukemic cells toward MSCs. Transfer of 
mitochondria, adhesion molecule ICAM1, and autophagosomes were significantly 
reduced when TNT signaling was inhibited. Mitochondria and membrane-associated 
proteins have previously been shown to be transported via TNTs by other cell types41-45, 
demonstrating the validity of our setup. Strikingly, transfer of autophagosomes was 
> 3.0-fold greater than the  transfer of other tested proteins and was also significantly 
disrupted by inhibiting TNTs. To our knowledge this is the first observation that TNTs 
transport autophagosomes. These structures are responsible for degrading damaged 
intracellular proteins and organelles46. Autophagosomes have a distinct double layered 
membrane, which is shaped through the actin cytoskeleton47. Since, TNT formation is 
also dependent on actin11,17 this co-dependence might be important for autophagosome 
transport through TNTs. Interestingly, starvation of cells, a potent inducer of autophagy, 
has been shown to increase the formation of TNTs48. Autophagy is a known regulator of 
cytokine signaling and this process is influenced by mitochondrial reactive oxygen species 
and/or mitochondrial DNA49.The transfer of mitochondria and autophagosomes from 
leukemic cells toward MSCs might therefore explain the release of supportive factors by 
the tumor microenvironment. In addition, both TNTs and autophagy have been shown to 
Elongation
1 2
Direct Contact Dislodgement
A
B
Figure 1. Two types of de novo TNT formation
Figure 1. Two types of de novo TNT formation. Figure illustrating two types of de novo TNT 
formation: (A) TNTs elongate from one cell and actively anchor to another cell. (B) After cell-cell 
contact, dislodgement leads to TNT formation.
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play a role in chemotherapy resistance of cancer cells17,50 and our data implies that these 
processes may be connected. 
LEUKEMIC CELL MIGRATION
A straightforward way to disrupt the leukemic niche is to induce clearance of leukemic 
cells from the bone marrow. Migration of leukemic cells is thought to be similar to that of 
hematopoietic stem cells (HSCs)51,52. HSCs migrate towards stromal cell derived factor 1 
(SDF1/CXCL12) which is actively produced by MSCs in the bone marrow51-53. The CXCL12 
receptor CXCR4 is highly expressed on both HSCs and leukemic cells13,51-53. Consequently, 
researchers have tried to disrupt the CXCR4/CXCL12 axis using small molecule inhibitors. 
These studies are mostly focused on acute myeloid leukemia (AML). Disruption of 
the CXCR4/CXCL12 axis led to mobilization of leukemic cells, increased sensitivity to 
therapeutic agents and prolonged survival in AML mouse models54-62. In ALL the effect 
of CXCR4/CXCL12 disruption is unclear. CXCR4 antagonists reduce engraftment of ALL 
cells in mouse models63,64, but paradoxically do not decrease the leukemic cell number in 
the bone marrow of leukemic mice63,65. In addition, CXCL12 expression is downregulated 
in murine bone marrow regions of extensive leukemia growth13. Finally, CXCL12 levels in 
the bone marrow of BCP-ALL patients are decreased compared to that of healthy controls 
and patients in remission53.
We investigated the migration of ALL cells using an ex vivo co-culture model with 
primary BCP-ALL cells and MSCs in chapter 5. Interestingly, we observed that ALL 
cells affect the migration potential of their microenvironment by inducing migration of 
leukemic counterparts and reducing migration of healthy HPCs and MSCs. Leukemic cells 
migrated 2.2fold more potently toward leukemic co-cultures (ALL-MSC) compared to 
MSC mono-cultures. This process is independent of the CXCR4/CXCL12 axis as CXCL12 
levels were unaltered in leukemic co-cultures. Moreover, CXCR4 inhibition was unable 
to inhibit the increase in migration toward the leukemic niche. These observations might 
explain the contradictory results of CXCR4 inhibition in ALL. Engraftment studies of ALL 
cells use mice that do not harbor leukemic cells in their bone marrow. Consequently, 
migration of cells is regulated by the healthy microenvironment and sensitive to CXCR4/
CXCL12 disruption13,51-53. In contrast, the bone marrow niche in mice suffering from ALL 
has been disrupted by leukemic blasts and uses alternative pathways. Our data shows 
for the first time that this leukemic niche is disrupted independently of CXCR4/CXCL12 
signaling. Next, we tried to identify which pathways might play a role in leukemic niche 
formation. We used a biased approach by quantifying the secretion of 64 cytokines in 
ALL-MSC co-cultures known to be important in immunology/hematology. The primary 
leukemic cells induced patient unique secretomes after co-culture with MSCs. Changing 
the source of MSC had no influence on the secreted factors showing that this process is 
governed by the leukemic cells. Interestingly all primary BCP-ALL cells induced MCP1/CCL2 
and/or MDC/CCL22 (CCR4-ligands), six out of ten induced IL-8 and/or GRO-1 (CXCR1/2-
ligands), and two out of ten induced IP10/CXCL10 (CXCR3-ligands). Importantly, we 
validated these findings using serum derived from bone marrow aspirates from 10 
ALL patients at diagnosis and compared them to samples from the same patients in 
remission. Furthermore, we used bone marrow aspirates of 7 healthy controls to analyze 
cytokine/chemokine patterns of the healthy niche. We observed an upregulation of CCR4 
and CXCR1/2 ligands in the serum of leukemic bone marrow. After induction therapy, 
the levels of CCR4 and CXCR1/2 ligands in the bone marrow of ALL patients decreased 
to levels observed in healthy controls. These data point to CCR4 and CXCR1/2 as valuable 
future therapeutic targets to interfere with the leukemic niche in ALL.
FUTURE PERSPECTIVES
TNT research is performed mostly in vitro, because these structures are difficult to image 
and no inhibitors are available that specifically disrupt TNTs. However, imaging methods 
are becoming more powerful and drive the study of increasingly smaller structures in 
vivo66,67. Multiphoton, or two-photon, confocal microscopy is especially suited for in vivo 
imaging because of its low background noise68,69. Recently, Osswald and colleagues used 
multi-photon microscopy to visualize TNT-like structures in brain tumors70. Moreover, 
multiple groups have shown the possibility of imaging hematopoietic cells in the bone 
marrow niche of mice13,71,72. In these experiments, hematopoietic cells were marked 
using lipophilic tracker dyes similar to those used in our TNT studies. Interestingly, HSCs 
have been observed to transfer lipophilic dye during in vivo experiments73. Experiments 
revealing the underlying mechanism have not yet been performed. These developments 
show the exciting opportunities for in vivo imaging of TNTs in the leukemic niche. 
We studied potential TNT disrupting compounds by screening inhibitors of 
the cytoskeleton in chapter 3. Other approaches for TNT disruption consist of finding 
novel genes that regulate TNT signaling. While limited, there have been reports on 
genes that regulate TNTs. Hase and colleagues investigated M-sec, also called tumor 
necrosis factor-α-induced protein 2, which is highly expressed in myeloid cells39. They 
showed that shRNA knockdown of M-sec in murine macrophages reduced the amount 
of TNT formation and decreased TNT length. In addition they provided evidence that 
M-sec cooperates with Ral and the exocyst complex39. The exocyst complex controls 
vesicle trafficking and the cytoskeleton74, while Ral is a small GTPase that plays a role 
in the (oncogenic) activation of proteins75. In addition to M-sec, Schiller et al. implicate 
the importance of LST1 in TNT formation between HeLa cells, by showing interaction 
between MSec, the exocyst complex, and Ral proteins18. However, the effect of M-sec 
or LST1 knockdown has not yet been reproduced using different cell types. An unbiased 
way to identify TNT-regulatory genes is to perform a large scale RNA interference screen. 
Huang et al. have demonstrated the value of such screens by revealing the pathway 
responsible for resistance to MEK and BRAF inhibitors in multiple cancers76. Our lab is 
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currently using RNA interference to investigate the effect of multiple candidate genes on 
lipophilic dye transfer from BCP-ALL cells toward MSCs. 
Identification of the molecules that are transported by TNTs is mostly performed by 
biased approaches. For example, we ectopically expressed a panel of fluorescent marker 
proteins in ALL cells and measured their transfer toward MSCs in chapter 4. Others 
have studied TNT signaling by using dyes that stain cellular compartments42. A non-
biased approach to study TNTs is the “Trans-SILAC” system, which uses stable-isotope 
labeling of amino acids in cell culture (SILAC). Cells labeled with heavy isotope proteins 
are co-cultured with a population of “light” acceptor cells. After co-culture, the two 
cell populations are high-purity sorted based on a fluorescent or membrane marker. 
The acceptor population is analyzed using mass spectrometry based proteomics, revealing 
which molecules have been transported between cell populations77. Using this method, 
Rechavi et al. have shown that oncogenic H-Ras transfers from cancer cells toward natural 
killer (NK) cells and T lymphocytes78. The pathway of transfer was unknown, but several 
years later Rainy et al. revealed that H-Ras transfers from B to T cells via TNTs43. Trans-
SILAC experiments with and without TNT inhibition provides a compelling method to 
characterize TNT signaling.
CONCLUDING REMARKS
The discovery of TNT signaling between ALL cells and MSCs may provide a novel therapeutic 
target for antileukemic therapy. Leukemic cells use TNTs to stimulate the secretion of pro-
survival cytokines in their microenvironment, subsequently inducing leukemic cell survival 
and drug resistance. Currently, it is unclear how to inhibit these cytoskeletal structures in 
the leukemic niche. The identification of new targets is strongly dependent on research 
that elucidates the molecular mechanisms driving TNTs. We show that TNT signaling 
in the leukemic niche is dependent on the interplay of actin regulating processes and 
cannot be disrupted by targeting tubulin. In addition, our data point to the importance of 
autophagosome and mitochondria transfer in this process. An alternative way to interfere 
with the leukemic niche is to induce clearance of leukemic cells from the bone marrow. 
Our data show that ALL cells modify their niche and induce the migration of leukemic 
counterparts, while inhibiting migration of healthy hematopoietic cells. This process was 
independent of CXCR/CXCL12. Instead we found the recurrent upregulation of CCR4 
and CXCR1/2 ligands. These data underline the importance of the leukemic niche and 
provide novel insights that may improve the future treatment of leukemia patients.
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KANKER
Het leven op aarde stamt af van een gemeenschappelijke voorouder die zich ongeveer 
3,5 miljard jaar geleden ontwikkelde. De samenwerking tussen simpele ééncellige 
levensvormen legde de basis voor de ontwikkeling van complexe meercellige organismen. 
Dit proces wordt elegant gevisualiseerd door het kweken van de bacterie Pseudomonas 
Fluorescens. Het DNA van individuele bacteriën muteert spontaan, waardoor ze een 
speciale lijm uitscheiden. Dit helpt in het vormen van zogenaamde “bacteriematten”, 
waar bacteriën samenwerken om meer zuurstof uit de lucht te halen. Op een zelfde 
manier, werken de 40,000 miljard cellen in ons lichaam samen om onze gezondheid te 
waarborgen. Soms wordt de samenwerking tussen cellen verstoord. In het voorbeeld van 
de bacterie Pseudomonas Fluorescens, ontstaan bacteriën die “valspelen” en gebruik 
maken van de bacteriematten zonder lijm te produceren. Dit leidt uiteindelijk tot het 
uiteenvallen van de matten en de dood van alle betrokken bacteriën. Cellen in het 
menselijke lichaam kunnen ook eigenschappen ontwikkelen die hen laat gedijen ten 
koste van het gehele organisme. Als deze cellen zich gedragen volgens verschillende 
kenmerken dan noemen we dit kankercellen. Kankercellen induceren groeisignalen, 
ontwijken groeionderdrukking, weerstaan celdood, delen oncontroleerbaar, induceren 
bloedvatvorming en dringen gezonde weefsels binnen. Kanker kan ontstaan uit 
elk weefsel in het menselijk lichaam en is één van de leidende oorzaken van sterfte 
wereldwijd. Het aantal mensen dat lijdt aan kanker stijgt naar verwachting met 70% in 
de komende decennia.
HET BLOEDSTELSEL EN BEENMERG
Alle cellen in het menselijk lichaam zijn verbonden aan het bloedvatenstelsel: een 
dynamisch netwerk van aders en slagaders die twee type bloedcellen transporteren. Rode 
bloedcellen transporteren zuurstof en koolstofdioxide, terwijl witte bloedcellen beschermen 
tegen infectieziekten. Bloedcellen stammen af van één celtype, de hematopoëtische 
stamcel (HSC), die wordt beschermd en gereguleerd door het beenmerg. HSCs creëren 
voorlopercellen die op hun beurt volwassen bloedcellen produceren. Myeloïde voorlopers 
produceren afweercellen die men al bij geboorte bezit, en lymfoïde voorlopers maken B- 
en T cellen die pas na blootstelling aan infecties ontwikkelen. Normale bloedcellen hebben 
een beperkte levensduur. Daarentegen kunnen HSCs zichzelf vernieuwen en nieuwe HSCs 
produceren. Deze bijzondere eigenschappen worden gedreven door chemische en fysieke 
signalen vanuit het beenmerg waarin HSCs zich bevinden. Het beenmerg micromilieu is 
rijk aan voedingsstoffen zoals “stromal cell-derived factor 1”, ook wel CXCL12 genoemd. 
Daarnaast bevat het een scala aan cellen, waaronder mesenchymale stromale cellen 
(MSCs), die cruciale cel-cel interacties bieden die HSCs onderhouden. Samen bepalen 
deze signalen de hiërarchie tussen HSCs en alle andere bloedcellen. HSCs zorgen dat het 
bloedstelsel continu wordt aangevuld, terwijl andere bloedcellen hun taak vervullen en 
daarna in apoptose (celdood) gaan.
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LEUKEMIE
Leukemie is een type kanker dat ontstaat in het beenmerg en de balans verstoord tussen 
bloedcellen. Het wordt veroorzaakt door witte bloedcellen die ongecontroleerd delen. Als 
leukemie niet wordt behandeld is het een dodelijke ziekte. Leukemie wordt geclassificeerd 
op basis van het gedrag van de kankercellen. Acute leukemie wordt veroorzaakt door een 
snelle toename van onrijpe witte bloedcellen, terwijl chronische leukemie jaren kan duren 
om te ontstaan. Dit proefschrift richt zich op acute lymfatische leukemie (ALL), de meest 
voorkomende doodsoorzaak van kanker bij kinderen. Meer specifiek kijken we naar B 
cel precursor ALL (BCP-ALL), de meest voorkomende vorm van ALL. BCP-ALL cellen zijn 
genetisch verschillend vergeleken met normale B cellen, door veranderingen in het DNA. 
BEHANDELING VAN LEUKEMIE
Het classificeren van leukemie op basis van genetische afwijkingen voorspelt 
de overlevingskans van de patiënt en de slagingskans van chemotherapie. Deze kennis is 
gebruikt voor het optimaliseren van de behandeling en hierdoor is de overleving gestegen 
van 10% in de jaren zestig tot 90% in de 21ste eeuw. Andere vormen van kinderkanker 
volgen deze trend en de gemiddelde overleving is rond de 80%. Deze progressie heeft 
ervoor gezorgd dat 1 op de 1000 twintigjarigen een overlever is van kinderkanker. Door 
een gebrek aan specifieke medicijnen hebben twee-derde van de overlevenden last van 
een chronische aandoening en in 28% zijn deze bijwerkingen zelfs levensbedreigend. 
Hartschade, longschade, littekens in de darmen, leverontsteking en levercirrose, nier- 
en blaasschade, botschade en krimping van de spieren, schildklierafwijkingen, obesitas, 
dwerggroei, onvruchtbaarheid, schade aan het centrale zenuwstelsel, oogschade, 
gehoorverlies, tand- en tandvleesschade; allen zijn bijwerkingen van chemo- en 
radiotherapie. Daarnaast hebben overlevenden van kinderkanker een 19-voud verhoogde 
kans op het ontwikkelen van een andere kanker. Dit onderstreept het belang van het 
ontwikkelen van nieuwe medicijnen die specifiek en effectief leukemiecellen doden.
KANKER IS EEN ZIEKTE VAN CELLEN DIE INTRINSIEK EN 
EXTRINSIEK AANGETAST ZIJN
Historisch gezien is kankeronderzoek gericht op het ontdekken van de intrinsieke 
veranderingen die kankercellen onderscheiden van gezonde cellen. Aan het einde van 
de 19de eeuw ontdekte David von Hansemann dat kankercellen zich op een afwijkende 
manier vermenigvuldigen en hierdoor hun DNA beschadigen1. Hij dacht dat deze 
beschadigingen verantwoordelijk waren voor het agressieve gedrag van kankercellen, 
maar de technologie was toen niet ver genoeg om dit te bewijzen. Naarmate de 
technologie verbeterde, bevestigden onderzoekers dat kankercellen worden getypeerd 
door schade aan het DNA. Ze ontdekten een verschuiving van DNA tussen twee 
chromosomen genaamd de BCR-ABL1 translocatie, of het Philadelphia chromosoom, 
die vaak voorkomt in leukemie. Doordat het DNA op een onjuiste manier vastzit, wordt 
een fusieeiwit gemaakt dat niet in gezonde cellen voorkomt. Dit BCR-ABL1 eiwit zorgt 
ervoor dat cellen hyperactief worden en ongecontroleerd groeien. De ontdekking van 
een fusieeiwit dat het gedrag van kankercellen stuurt, maakte het mogelijk om specifieke 
medicijnen tegen kankercellen te ontwikkelen. Het leidde tot de ontwikkeling van imatinib, 
een remmer van het BCR-ABL1 eiwit. De overleving van leukemiepatiënten is aanzienlijk 
gestegen sinds het gebruik van dit medicijn. Dit is een voorbeeld van hoe schade aan 
het DNA het gedrag van kankercellen aanstuurt en dat dit doelwitten kunnen zijn voor 
specifieke medicatie. 
Behalve afwijkingen aan het DNA is ook bewijs aanwezig dat kankercellen niet 
onafhankelijk functioneren, maar gedreven worden door hun omgeving. Al in 
1889 viel het Stephen Paget op dat als kankercellen zich verspreiden in het lichaam, 
ze een voorkeur hebben voor specifieke organen. Hij besprak dit in zijn “zaai en 
oogst” hypothese, waarin hij het uitgroeien van kankercellen vergeleek met dat van 
plantenzaad. Paget zei: “Een plant verspreid zijn zaden in alle richtingen. Maar de 
zaden zullen alleen overleven en uitgroeien als ze op vruchtbare grond vallen.” In een 
soortgelijke manier hebben kankercellen ook een specifieke omgeving nodig om in te 
groeien. Dit werd ondersteund door zijn observaties dat borstkanker vaker uitzaaide in 
de lever dan in andere organen. Daarnaast zijn observaties gedaan waar kankercellen in 
bedwang werden gehouden door hun omgeving. Muis embryo’s werden geïnjecteerd 
met kiemceltumorcellen, maar groeiden uit tot gezonde muizen zonder kanker. De 
tumorcellen waren nog steeds aanwezig maar werden door de omringende cellen 
aangezet om gezonde taken uit te voeren. Deze observaties laten zien dat cellen zich niet 
gedragen als onafhankelijke entiteiten, maar als een systeem dat wordt gedreven door 
complexe communicatiemechanismen. Kanker kan dus beter beschreven worden als een 
ziekte van zowel intrinsiek als extrinsiek aangetaste cellen. De invloed van cellen rondom 
de tumor, ofwel het tumor micromilieu, is een opkomend veld binnen leukemieonderzoek. 
Het leukemische micromilieu induceert chemotherapie resistentie en is cruciaal voor 
het ontstaan van leukemie. Groeifactoren en celcel interacties zijn belangrijk in dit 
proces. Onze huidige kennis schiet echter tekort in het verklaren hoe het leukemische 
micromilieu wordt gereguleerd en gecontroleerd. Dit is waarom we geïntrigeerd waren 
door de ontdekking van een nieuw communicatiemechanisme tussen cellen: tunneling 
nanotubes (TNTs). TNTs zijn dunne buizen die cellen verbinden en een grote variatie 
aan signaalmoleculen kunnen overbrengen. Kankercellen zouden TNTs kunnen gebruiken 
om de cellen in hun omgeving aan te tasten en tegelijkertijd zichzelf te beschermen. 
De aanwezigheid en het belang van TNTs waren onbekend en zijn onderwerp van het 
onderzoek beschreven in dit proefschrift. 
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ONTDEKKING VAN TNT SIGNALERING TUSSEN LEUKEMIECELLEN 
EN BEENMERGCELLEN
Al snel na de ontdekking van TNTs observeerden onderzoekers dat witte bloedcellen ook 
TNTs maken. Toentertijd waren geen studies die TNTs in leukemie hadden onderzocht en 
daarom onderzochten we dit in Hoofdstuk 2. We ontdekten dat leukemiecellen onderling 
TNTs maken en hiermee actief signalen uitwisselen. Daarna bekeken we de TNT signalering 
tussen leukemiecellen en MSCs, een belangrijke cel uit het beenmerg. Verbazingwekkend 
vormden leukemiecellen veel meer TNTs naar MSCs dan naar andere leukemiecellen. 
Deze communicatie via TNTs zorgde voor de uitscheiding van overlevingsfactoren 
en een verhoogde resistentie tegen prednisolone, één van de belangrijkste medicijnen 
tegen leukemie. Het verbreken van TNTs leidde tot celdood van leukemische cellen 
en een verhoogde gevoeligheid voor prednisolone. Deze bevindingen laten zien dat TNTs 
een rol spelen in de communicatie van leukemiecellen met hun omgeving.
HET VINDEN VAN NIEUWE TNT REMMERS
De ontdekking van TNT signalering in de leukemische niche was gedaan met zogenaamde 
ex vivo proeven (ex vivo = buiten het lichaam). Tijdens ex vivo proeven worden TNTs 
geremd door het schudden van cellen (mechanische disruptie) of het verbreken van direct 
cel contact door het gebruik van speciale filters. Helaas zijn deze technieken niet toe 
te passen op diermodellen of mensen. Daardoor is een grote vraag naar specifieke TNT 
remmers. Om nieuwe TNT remmers te identificeren hebben we een systeem opgezet 
dat nauwkeurig TNT signalering kan meten in Hoofdstuk 2. We gebruikten hiervoor 
een speciale kleurstof die moleculen aankleurt die door TNTs worden overgebracht 
tussen cellen. Gekleurde leukemiecellen werden gekweekt met ongekleurde MSCs en de 
verplaatsing van kleur werd gebruikt als een maat van signalering. TNTs zijn structuren 
die worden gemaakt door het cytoskelet van cellen. Dit cytoskelet is opgebouwd uit 
eiwitten die zorgen voor stevigheid en beweeglijkheid. We hebben een grote hoeveelheid 
remmers getest die een effect hebben op de cytoskeletale eiwitten actine en tubuline. Het 
remmen van tubuline leidde niet tot verminderde TNT signalering. In tegendeel, tubuline 
remmers induceerden TNT signalering meer dan tweevoud. Daarentegen resulteerde het 
remmen van actine in een sterke vermindering van TNT signalering (meer dan 20-voud). 
Deze bevindingen laten zien dat actine cruciaal is in het proces van TNT signalering tussen 
leukemiecellen en MSCs.
TOXICITEIT VAN ACTINE REMMERS
Het verstoren van het cytoskelet wordt al langer gebruikt als kankertherapie. Het gaat 
hier om tubuline remmers die de celdeling van kankercellen remmen. Deze medicijnen 
zijn erg effectief, maar veroorzaken heftige bijeffecten, zoals schade aan zenuwen, het 
hart en een vergrote kans op bloedproppen. Desalniettemin, worden tubuline remmers 
gezien als één van de meest succesvolle kankermedicijnen. Wij hebben de invloed van 
actine remmers getest op de overleving van leukemiecellen en verschillende soorten 
gezonde bloedcellen. We observeerden dat een aantal gezonde bloedcellen de actine 
remmers beter verdragen dan leukemiecellen. Actine remmers zouden in de toekomst 
een nieuw type leukemie medicijn kunnen worden die zowel de leukemiecel doden als 
de communicatie tussen leukemiecellen en hun micromilieu kunnen verbreken.
TNT STRUCTUUR EN SIGNALERING ZIJN AFHANKELIJK VAN HET 
CELTYPE
In Hoofdstuk 2 en 3 hebben we gezien dat TNTs in de leukemische niche structuren 
overbrengen tussen cellen. In Hoofdstuk 4 probeerden we te identificeren welke moleculen 
getransporteerd worden van leukemiecellen naar MSCs via TNTs. Hiervoor gebruiken 
we fluorescent gelabelde moleculen die we tot expressie brachten in leukemiecellen. 
Deze moleculen markeren specifieke structuren in de cel. De gelabelde leukemiecellen 
werden vervolgens gekweekt met ongelabelde MSCs en de overgang van deze gekleurde 
structuren werd gemeten. Wij observeerden dat adhesiemoleculen, mitochondriën en 
autophagosomen werden getransporteerd via TNTs. De overdracht van adhesiemoleculen 
zou de TNT-verbinding tussen cellen kunnen versterken. Mitochondriën zijn structuren die 
de cel voorzien van energie, terwijl autophagosomen eiwitten en voedingsstoffen recyclen. 
Beide zijn bekend een rol te spelen in de uitscheiding van overlevingsfactoren. Het zou 
kunnen dat leukemiecellen mitochondriën en autophagosomen transporteren naar cellen 
in hun omgeving om hen aan te zetten tot het produceren van overlevingsfactoren. Dit zou 
een mogelijk mechanisme kunnen zijn dat de overleving en resistentie van leukemiecellen 
tegen medicijnen verhoogd.
LEUKEMISCHE CEL MIGRATIE
Het ontcijferen van moleculaire mechanismen die het ontstaan van een leukemische niche 
stimuleren zou kunnen leiden tot nieuwe therapeutische strategieën. Een vanzelfsprekende 
manier om de leukemische niche te verstoren is om de leukemiecellen te verdrijven uit 
het beenmerg. De migratie van leukemiecellen wordt gedacht hetzelfde te zijn als die 
van HSCs. HSCs migreren naar CXCL12 toe, een stof die actief wordt geproduceerd 
door MSCs in het beenmerg. HSCs en leukemiecellen hebben beiden een hoge expressie 
van CXCR4, de receptor die CXCL12 opvangt. Onderzoekers hebben geprobeerd om 
de interactie tussen CXCR4 en CXCL12 te verstoren door middel van specifieke remmers. 
Op deze manier lukte het om de migratie van leukemiecellen naar een gezond beenmerg 
te remmen. Als het beenmerg echter al vol zat met leukemiecellen, werden deze cellen 
niet meer verstoord door CXCR4/CXCL12 remming en bleven ze in het beenmerg zitten. 
Daarnaast is de uitscheiding van CXCL12 in het beenmerg verminderd in gebieden van 
veel leukemiecellen. Deze bevindingen duiden op het belang van andere mechanismen 
dan CXCR4/CXCL12 in de leukemische niche.
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Wij onderzochten de migratie van ALL cellen met behulp van ex vivo culturen van 
BCP-ALL cellen en MSCs in Hoofdstuk 5. We toonden aan dat leukemiecellen het 
beenmerg veranderen en hierdoor MSCs aanzetten om nog meer leukemiecellen aan 
te trekken en gezonde bloedcellen te weren. Dit proces was onafhankelijk van CXCR4 
en CXCL12. Wanneer leukemiecellen in contact kwamen met MSCs induceerden ze de 
stoffen MCP-1/CCL2 en/of MDC/CCL22. Deze moleculen binden aan de CCR4 receptor, 
die hoger tot expressie komt in ALL cellen in vergelijking met gezonde bloedcellen. Ook 
kwamen in sommige gevallen liganden vrij voor CXCR1, CXCR2 en CXCR3 receptoren. 
Deze bevindingen laten zien dat CXCR4/CXCL12 inhibitie niet succesvolle is in het 
verstoren van het leukemische micromilieu en ze onthullen nieuwe mogelijke doelwitten 
voor therapie.
SLOTBESCHOUWING
De ontdekking van TNTs tussen ALL cellen en MSCs zou kunnen leiden tot een nieuw 
therapeutisch doelwit voor leukemie. Leukemische cellen gebruiken TNTs om de secretie 
van overlevingsfactoren te stimuleren die overleving en drugsresistentie induceren. 
Helaas zijn op dit moment TNT remmers niet specifiek genoeg om te gebruiken in 
de kliniek. De ontdekking van nieuwe remmers is sterk afhankelijk van onderzoek dat 
de moleculaire mechanismen ontrafelt die TNTs aansturen. Wij laten zien dat TNT 
signalering in de leukemische niche afhankelijk is van actine en niet verstoord kan worden 
door het remmen van tubuline. Daarnaast hebben we aanwijzingen dat autophagosomen 
en mitochondriën een belangrijke rol spelen in dit proces. Een alternatieve manier om 
de leukemische niche te verstoren is om leukemiecellen te verdrijven uit het beenmerg. 
Onze experimenten tonen aan dat leukemiecellen hun micromilieu veranderen en 
hierdoor de migratie stimuleren van andere leukemiecellen en de migratie van gezonde 
bloedcellen remmen. Dir proces was onafhankelijk van CXCR4/CXCL12. In plaats 
daarvan zagen we de secretie van liganden van CXCR1/2 en CCR4 receptoren. Deze 
data onderstrepen het belang van de leukemische niche en geven nieuwe inzichten die 
de therapie van leukemiepatiënten in de toekomst zou kunnen verbeteren.
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